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Human liver progenitor cells are potentially useful for a wide variety of 
clinical applications such as transplantation, bioartifical liver, drug 
development and gene therapy. Current gaps in understanding of the key 
mechanisms that drive progenitor cells proliferation and maturation have 
limited the realization of their full potential. We aimed to determine the key 
message signals that drive progenitor cell proliferation and differentiation in 
developing fetal liver and determine their implication in regenerative 
medicine. Our aim is to determine the key message signals that drive 
progenitor cell proliferation and differentiation in developing human fetal 
liver and determine their functionality and application in regenerative 
medicine. Human fetal livers from 10 weeks to 24 weeks gestation were 
obtained with full consent. These samples were characterized with IHC, 
microarray, next generation sequencing and qRT PCR for growth factor, 
extracellular matrix and transcriptional factors. Comparison was made with 
adult normal livers. Using immunophenotyping and transcript signature, 5 
phases were distinguished and categorized in fetal liver development. Fetal 
liver progenitor cell undergoes proliferation at 10 to 14 week gestation, from 
14 to 18 weeks differentiation of fetal hepatic lineage - the hepatoblast form, 
in week 18 there are signs of hematopoietic lineage expression from liver and 
from week 20 onwards there is a sudden proliferation of EpCAM and 
Vimentin positive cells, which is seems to be a mesenchymal lineage. 
EPCAM/CD44+ progenitor cells appear at 10 weeks and undergo surge in 
proliferation at 18-20 weeks of gestation before dwindling in frequency. The 
expression pattern of EPCAM corroborate that there are distinct phases such 
 xiv 
 
as progenitor cell population surge at 10 weeks, hepatoblast proliferation 
from 10 to 14 weeks, hematopoietic phase at 15-18 weeks and reactivation to 
22 weeks. This suggests that epithelial cell proliferation appears to take a 
backstage during the hematopoietic phase but undergo a second wave of 
progenitor cell proliferation with resurgence with termination of the 
hematopoietic phase. This was accompanied by increase in albumin and 
CYP450 gene expression compared to the 10 week fetal liver validating the 
maturation of fetal liver at this stage.  
Week 10-11 Specification phase - genes at this stage were mostly embryonic 
stem cell factors and would be useful for in vitro IPSC manipulation. Week 
14-15: Expansion / differentiation phase - Genes at this stage were 
extracellular matrix proteins Collagen, Laminin and Hyaluronic acid. Week 
17-19: Hematopoiesis and Proliferation Week 20-24: Maturation, EMT phase 
- genes that were upregulated at this stage were FGF, FGFR and CTGF. 
Adult Liver: functional. Specifically, week 11 to 14 would represent the 
phase of hepatoblast playing the role of a transit-amplifying cell in expansion 
and differentiation into hepatic lineage. Similarly, week 19 to 22 would 
represent the phase of progenitor cell proliferation by mesenchymal epithelial 
transition. Week 23 to adult would represent the phase of hepatocyte 
maturation.  
We have also identified key genes in each phase and are classified under 
transcriptional factors (GATA4, FOXA2 and CEBPa), growth factors (FGFR 
and CTGF) and extracellular matrix (COL12A1, LAMA3, Fibronectin and 
Hyurolic Acid). The progenitor liver cells were transplanted into SCID mice 
treated with thioacetamide and the degree of repopulation was analyzed. In 
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vivo transplantation of these cells in mice livers showed positive correlation 
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The liver is a complex organ constituted of cells, such as hepatocytes, 
hepatocyte precursor cells (Scadden, 2006), stellate cells, kupffer cells, 
epithelial cells, sinusoidal epithelial cells, biliary epithelial cells, and 
fibroblasts(Kmiec, 2001). Hepatocytes make up to about 80% of the liver 
mass and are the primary functional cells in the liver. The cells are granular, 
protoplasmic; contain glycogen, fat or an iron compound. It is an important 
organ in our body that does physiological functions including metabolic 
reactions, energy storage, serum protein production, bile secretion, and 
defense against pathogenic infections. Liver disease is spread worldwide. The 
World Health Organization (WHO) estimated in 2013, death by liver cancer 
was increased to 50 million per year over last 2 decades.  It was also reported 
that approximately1.3 million deaths worldwide are due to chronic viral 
hepatitis. It was reported that hepatic failure alone, reports for 1-2 million 
deaths per annum, and the main causes including: excessive alcohol 
consumption, aggressive forms of fatty liver disease, fibrosis, inflammatory 
liver conditions and unregulated ingestion of common over-the-counter 
medication, such as acetaminophen (Tynelol) (Rozga, 2006).  
Although the liver disease has significant morbidity and mortality worldwide, 
medical advancement so far allows successful treatment for resection and 
transplantation surgeries only (Schwartz, 2014). This is an invasive procedure 
and is restricted by the availability of donor organs. Less than 23% of patients 
are on a waiting list to receive a transplant (Bellamy et al., 2001, Cowling et 
al., 2004).  




Although Liver transplantation is currently the only option for treating both 
acute hepatic failure or end stage liver disease, a major and serious limitation 
is donor shortage. Recent advancement has turned its attention on identifying 
alternative mode of management for fatal liver disorders with regenerative 
medicine. Embryonic stem cells (ESC) provided alternative solution offering 
potential source of human hepatocytes. However, the limitation of using 
ESCs is that the production of large quantities of homogenous cells/tissue for 
clinical application. It has been well documented that there could be potential 
complications associated with the animal feeder layers on which human ES 
cells tend to rely on in addition to the risk of teratomas. Therefore the use of 
ESC remains a distant source for clinical application. The breakthrough 
techniques by Takahashi and Yamanaka for pluripotency induced in adult 
fibroblast gives an attractive alternative for ESC (Takahashi and Yamanaka, 
2006). These induced pluripotent stem cells can be generated without ethical 
concerns, but their genome instability and low efficiency of cell production 
raises the same concerns as for ESCs when considering their clinical use.  
Fetal liver progenitor cells have been identified and have been successfully 
differentiated into hepatocyte or bile epithelial cells (Rogler, 1997, Kubota 
and Reid, 2000, Dan et al., 2006) Kubota and Reid 2000). Previous studies 
have demonstrated in rat models that fetal hepatic stem/progenitor cells 
exhibited potency for reconstitution of adult liver but only under a specific set 
of conditions (Oertel et al., 2008). It is still unclear whether fetal liver 
progenitor cells, can reconstitute recipient livers not subjected to genetic 
modification. Its been reported that expansion of hepatocytes were 
compromised by phenotypic changes and karyotypic abnormalities over 




prolonged culture durations (Delgado et al., 2005).  
Hepatocyte transplantation is believed to be a potential solution to this 
problem. Human hepatocytes are in great demand for different purposes in 
translational research. In clinical applications, they could potentially be useful 
when transplanted directly into patients with liver failure or genetic disorders 
(Fox et al., 1998) or when employed in bioartificial liver devices for liver 
dialysis (Sussman et al., 1994). Although liver transplant is curative for many 
of these diseases, the complexity of the surgical procedure and shortage of 
healthy donor graft has limited the ability to transplant most patients with 
liver diseases. In fact, given the endemicity of Hepatitis B in Asia and 
epidemic of Hepatitis C in Western countries, the waiting list for transplant 
has grown exponentially and more patients are waiting longer on the list and 
dying before they can receive a transplant.    
In addition, large numbers of human hepatocytes are needed for toxicology 
studies for drug development in the pharmaceutical industry. Testing of 
absorption, distribution, metabolism and excretion as well as toxicity in liver 
are considered as critical steps in new drug development. The use of reliable 
ex-vivo hepatocytes will allow rapid testing of drugs and reduce the need for 
exposing humans to phase 1 trial if hepatotoxicity can be detected earlier.  
The major hurdles that have limited the use of human hepatocytes, are the 
lack of a continual, reliable source of cells and the technical difficulty 
involved in maintaining their differentiated hepatocytic functions in vitro for 
significant period of time (Leffert et al., 1978). Following liver injury, the 
human hepatocyte possesses tremendous intrinsic ability to proliferate and 




regenerate itself in vivo (Fausto, 2004). However, despite the rapid advances 
in understanding the liver anatomy and physiology, it has not been possible to 
proliferate human hepatocytes reliably in culture or prevent them from 
dedifferentiation and losing their hepatocytic functions. 
As a result of these limitations, there have been significant efforts to identify 
and utilize alternative sources of cells that can be expanded easily in culture, 
and subsequently manipulated to give rise to hepatocytes, either by directed 
differentiation (hepatocyte linage stem/ progenitor cells) or 
transdifferentiation  (stem cells from other lineages)(Dan and Yeoh, 2008). 
Candidate cells that have been reported to have this potential includes 
embryonic stem cells, hematopoietic stem cells, mesenchymal stem cells 
(MSC) or mesenchymal lineage stem cells, fetal liver progenitor cells, adult 
liver progenitor cells or more recently, induced pluripotent stem cell or 
reprogrammed somatic cell(Dan and Yeoh, 2008).   
The knowledge gained from the exploration of these steps from lab to bedside 
is important in attempting to use these cells for therapeutic application. We 
believe both these cell types are easier to convert, as hepatocytes are 
amenable to scale up cultures to provide large numbers of hepatocytes in a 
safe, efficient way in comparison with mesenchymal stromal cells 
Limitation in past studies includes: 1. No systematic temporal expression 
studied on human fetal liver developmental stages and its regulatory 
mechanisms. 2. Our gaps in knowledge about the liver maturation. 3. 
Understanding the microenvironment during development helps to close the 
gap in culture system. Using this knowledge could bring us closer to liver 




disease treatment in a promising way. In this study we have focused on 
temporal expression of human fetal liver development during the second 
trimester. We hypothesize that the fetal compared to adult liver environment, 
would shed light on the key maturation signals that drive fetal liver progenitor 
cell proliferation and differentiation.  
1.2 Literature review of previous studies on liver development in animal 
models 
Liver development is a complex process of distinct biological events. Each 
stage of differentiation is controlled by mechanisms in addition to the 
extracellular signals. During the last decade, substantial progress has been 
made in understanding the molecular mechanisms that direct early aspects of 
mammalian liver development. Studies using tissue explant cultures and 
molecular biology methods in addition to the analysis of the transgenic and 
knockout mice have identified signaling molecules and transcription factors 
which are required for the establishment of hepatogenesis. 
1.3 Hepatic lineage Specification  
During gastrulation, liver is derived from the endoderm, one of the three germ 
layers. The endoderm defines the primitive gut and gives rise to the epithelial 
compartment of the gastrointestinal tract. The endoderm also gives rise to 
other organs including the pancreas and the thyroid gland (Lemaigre, 2009).  
Fate mapping studies in mice where endodermal cells were labeled with a dye 
showed that liver progenitor cells originate from three endodermal domains: 
two domains are paired and located laterally, and the third domain is found 
along the ventral midline (Tremblay and Zaret, 2005, Zaret, 2008). 




Experiments based on tissue explants and genetically engineered animal 
model have revealed a number of important mechanisms underlying liver 
specification (Zaret, 2002, Lemaigre and Zaret, 2004). 
1.3.1 Specifying the hepatic lineage by cardiac mesoderm  
A crucial question in the area of the gut organogenesis is how individual 
tissues are specified at different domains along the antero-posterior axis of the 
endoderm. Studies in model organisms have shown that endodermal domains 
are usually patterned by interactions with overlying mesodermal tissue 
(Douarin, 1975). The classical tissue transplantation studies performed by 
LeDouarin, using chick embryos, showed that cardiogenic mesoderm, which 
is transiently in the close vicinity of the prospective hepatic endoderm, 
provides a signal that is crucial for inducing liver progenitors in endoderm 
(Douarin, 1975).  
On the other side mesoderm from other areas of the chick embryo does not 
induce the liver. Interestingly, at an earlier stage, the endoderm itself is 
important for inducing cardiogenic mesoderm (Sugi and Lough, 1995). 
Fibroblast growth factors (Fgfs) signaling from the cardiac mesoderm induces 
the liver in the ventral foregut endoderm. At the time of hepatogenesis, the 
cardiogenic mesoderm express at least three out of the eighteen known Fgfs, 
and the ventral foregut endoderm expresses at least two of the four tyrosine 
kinase Fgf receptors (Jung et al., 1999). At the time of hepatic induction, the 
endoderm uniquely expresses Fgf receptor 4 (Fgfr4) (Stark et al., 1991) and 
both the endoderm and cardiac mesoderm express Fgf receptor 1 (Fgfr1) 
(Sugi and Lough, 1995). In situ immunohistiochemistry studies showed that 




Fgf1 and Fgf2 are both induced in the cardiac mesoderm at the 7-8 somite 
stages in mouse(Jung et al., 1999). Purified Fgf1 and Fgf2 were each found to 
efficiently induce early liver-specific genes within the ventral foregut 
endoderm, when the endoderm was isolated from 2-6 somite stages. The 
induction of serum albumin (Alb), α-fetoprotein (Afp), and transthyretin 
(Ttr), was as strong as that induced by cardiac mesoderm. In contrast, Fgf8 
had only partial hepatogenic activity and it failed to induce hepatic 
development. However, it was found to contribute toward the morphogenic 
outgrowth of the hepatic tissue following specification. The early expression 
of Fgf8 or a related molecule appears to strengthen the morphogenetic 
activity of the emerging hepatic cells. It appears, that Fgf8 works together 
with a signal that has not been identified to stimulate cell outgrowth (Jung et 
al., 1999).  
The isolated ventral foregut endoderm does not remain undifferentiated when 
it is cultivated without cardiogenic mesoderm or Fgfs. Rather; it starts the 
expression of pancreatic genes, as a default lineage (Deutsch et al., 2001). Fgf 
or cardiogenic mesoderm suppress the pancreatic program in the endoderm 
and induces the liver program. So ventral foregut endoderm consist of a 
multipotential cell population that undergoes a cell-fate choice during spatial 
patterning. The ventral pancreatic bud derives from the most distal endoderm 








1.3.2 Specifying the hepatic lineage by septum transversum mesenchyme  
The early chick studies of LeDouarin identified a second stage of hepatic 
induction, which appears when mesoderm derived cells in the septum 
transversum promote growth and further differentiation of the newly specified 
hepatic endoderm (Douarin, 1975, Fukuda-Taira, 1981).  
These additional hepatogenic signals originate from septum transversum 
mesenchyme (STM) cells. The septum transversum derives from lateral plate 
mesoderm and gives rise to the epicardium of the heart and also the 
diaphragm. Before hepatic induction, prospective septum transversum 
mesenchyme cells surround the developing cardiac re- gion near the ventral 
foregut endoderm. Bone morphogenetic proteins 2 and 4 (Bmp2 and Bmp4) 
are strongly expressed in the STM, before and during hepatic induction.  
(Rossi et al., 2001) confirmed that STM collaborate with developing cardiac 
tissue to control specification of the liver lineage. The role of Bmp4 signaling 
during the onset of hepatogenesis has been confirmed by experiments with 
Noggin (Bmp4 antagonist). This molecule was found to inhibit albumin 
mRNA expression in co-culture of cardiac tissue and 2-6 somite stage ventral 
endoderm. This result was contradictory with previous finding by Jung et al. 
in that FGF alone was sufficient to induce hepatogenesis within cultured 
ventral endoderm. However, the endoderm cultures contained small numbers 
of Mrg1 positive cells, which is a marker of STM. The amount of STM cells 
was sufficient to supply a sufficient amount of Bmps to allow hepatic 
induction by exogenously added FGFs (Rossi et al., 2001). Additionally, for 
the induction of hepatogenesis, secretion of Bmps by STM appears to be 




critical for outgrowth of the budding hepatoblasts. The Fgfs and Bmps act in 
a concert manner on the ventral foregut endoderm to direct the onset of 
hepatogenesis.  
The Hlx knockout embryos additionally confirmed the STM role in 
controlling developmental growth of the liver. Hlx gene encodes a homeobox 
transcription factor and its expression in developing liver is restricted to cells 
derived from STM. Mouse embryos lacking the Hlx gene start the liver 
development normally, however, by E15.5 the mutant livers had failed to 
expand and reached only 3% of the size of control livers (Hentsch et al., 
1996). Although the targets of Hlx are not known, it must be required for 
expression of paracrine factors, from STM, that control hepatogenesis (such 
as hepatocyte growth factor (HGF)).  
1.3.3 Hepatic gene induction in embryonic endoderm cells  
The tissue interactions described the exact location and timing of 
hepatogenesis during embryonic development. At least three different kinds 
of mesoderm cells, including the cardiac mesoderm (Douarin, 1975, Gualdi et 
al., 1996), the septum transversum mesenchyme (STM) (Rossi et al., 2001), 
end endothelial cells (Cleaver and Melton, 2003), coordinately induce liver 
development in the endoderm, apparently by employing different signaling 
molecules (Zaret, 2002, Duncan, 2003b). Nevertheless, the mechanisms by 
which the cells of the endoderm really follow and adopt a hepatic fate are best 
considered as intracellular responses to these signals. The intracellular 
network by which FGF signaling helps induce hepatic genes and stabilize 




emerging hepatic cells within the endodermal epithelium has just recently 
been elucidated.  
FGF-mediated induction of hepatic genes function through the MAPK 
pathway and not the PI3K/AKT pathway. Although the PI3K/AKT pathway 
is activated in foregut endoderm cells, its inhibition does not block hepatic 
gene induction in explants; however it does block tissue growth. At the 
beginning of hepatogenesis, the FGF/MAPK and PI3K/AKT pathways are 
induced separately in the foregut endoderm and do not cross- regulate at the 
initial stages of tissue patterning (Calmont et al., 2006). The inherent ability 
of FGF to activate MAPK and not PI3K in the foregut endoderm helps define 
the intracellular network that give the endoderm cells the ability to induce 
liver and explain how a common signal such as FGF trigger a specific cellular 
response. There is a strong correlation between the expression of different 
FGF ligands and phospho-ERK activation during the period of hepatic 
specification. Although FGFs represent a proliferative signal for the 
endoderm shortly after tissue patterning (Bhushan et al., 2001)and MAPK 
signaling can stimulate cell proliferation (Lavine et al., 2005). Calmont et al. 
demonstrated that FGF/MAPK signaling initiates the hepatic differentiation 
and that it is distinct from the effects on cell proliferation and growth.  
1.3.4 Growth of hepatic endoderm into the liver bud  
The liver emerges from the definitive gut endoderm first as a thickening of 
the ventral endoderm epithelium and then as a bud of cells that proliferates 
and migrates into the surrounding septum transversum mesenchyme. The 
septum transversum is a collagen-rich environment colonized by loosely 




joined mesenchyme cells (Cascio and Zaret, 1991), which defines the area of 
the embryonic body cavity into which the hepatic bud grows. These pre-
hepatic cells, which delaminate from the foregut and migrate into septum 
transversum are called hepatoblasts (Medlock and Haar, 1983). Their 
analyses in culture suggest that they are bipotential, capable of giving rise to 
both the hepatocyte and cholangiocyte cell lineages (Rogler, 1997). As the 
hepatoblasts migrate they closely associate with primitive sinusoidal 
endothelial cells that form capillary-like structure between the migrating 
hepatic strings (Enzan et al., 1997). The hepatoblast have irregular shape, 
large nuclear to cytoplasmic ratio and relatively few organelles when 
compared to mature hepatocytes. The process of differentiation of hepatoblast 
to hepatocyte is gradual, taking several days during development of the 
rodent embryo.  
After the liver bud is generated, it appears that other groups of growth 
signaling pathways are involved in further liver specification. These signals 
are, hepatocyte growth factor (HGF), oncostatin M (OSM) and 
glucocorticoids.  
Hepatocyte growth factor (HGF) is a powerful mitogen originally discovered 
to play a role in the regeneration of the adult liver, after partial hepatectomy 
(Michalopoulos and DeFrances, 1997). The HGF/c-Met pathway mediates the 
interaction between mesenchyme and epithelial cells during development 
since HGF is expressed in the STM that surrounds the developing liver bud, 
and c-met, the HGF receptor, is expressed on embryonic hepatocytes 
(Schmidt et al., 1995). Mice lacking HGF fail to complete development and 




die in uterus. The mutation affects the embryonic liver, which is reduced in 
size and shows extensive loss of parenchymal cells. In addition, development 
of the placenta, mainly of trophoblast cells, is impaired. Thus, HGF is 
essential for the development of several epithelial organs (Schmidt et al., 
1995).  
Hematopoiesis plays an important role in hepatic maturation. After the liver 
bud emerges from the gut tube, hematopoietic cells migrate there and 
propagate. The hematopoietic cells produce oncostatin M (OSM), a growth 
factor belonging to the interleukin-6 (IL-6) family (Zarling et al., 1986). In 
the developing liver, OSM is ex- pressed by CD45+ hematopoietic cells, but 
not by hepatocytes. OSM stimulates the expression of hepatic differentiation 
markers and induces morphologic changes and multiple liver-specific 
functions like ammonia clearance, lipid synthesis, glycogen synthesis, 
detoxification, and cell adhesion. With the maturation of bone marrow and 
spleen around birth, hematopoiesis in the liver reduces and hematopoietic 
stem cells migrate from the liver to the organs responsible for adult-type 
hematopoiesis (Kinoshita and Miyajima, 2002). While OSM expression in the 
liver starts in mid gestation and de- creases in postnatal stages, HGF is mainly 
expressed in the liver during the first few days after birth. OSM and HGF 
induce hepatic maturation through different signaling path- ways. Hepatic 
maturation induced by OSM depends on STAT3 and HGF-induced 
differentiation is STAT3-independent. Like OSM, HGF in the presence of 
dexamethasone induced expression of glucose-6-phosphatase (G6P), tyrosine 
amino transferase (TAT), and accumulation of glycogen in fetal hepatic cells, 
but at a lower level than OSM. Both OSM and HGF induce production of 




albumin (ALB) but its secretion appears only in response to OSM (Kamiya et 
al., 2001).  
Glucocorticoids are involved in hepatic maturation and alter the proliferation 
and function of adult hepatocytes. In the fetal liver, physiological 
concentration of dexamethasone (Dex), a synthetic glucocorticoid, suppress 
α-fetoprotein (AFP) production and DNA synthesis and promote albumin 
(ALB) production. OSM alone fails to induce differentiated liver phenotypes, 
implying the importance of glucocorticoids as triggers for hepatic maturation 
(Kinoshita and Miyajima, 2002). 
1.3.5 Other molecules affecting hepatogenesis 
Other signaling molecule affecting the developing hepatocytes is 
transforming growth factor β (TGFβ). Liver development was found to be 
severely disturbed in Smad2+/− and Smad3+/− mouse embryos at E14.5 
(Weinstein et al., 2001). The presence and composition of extracellular matrix 
(ECM) has a significant effect on the gene expression profiles of cultured 
primary hepatocytes (Michalopoulos et al., 2001). A role of ECM signaling 
during the development of the liver emanate from studies of β-1 integrin. 
Chimeric mice generated by combining wild type embryos with β-1 
integrin−/− ES cells showed that cells lacking β-1 integrin were unable to 
colonize the liver. Hence, there is a requirement for β-1 integrin in defining or 
maintaining the hepatocyte cell lineage (Fassler and Meyer, 1995). 
1.4 Transcriptional regulation of early hepatogenesis 
The creation of the liver occurs in a two-step process, beginning with the 
establishment of competence in the foregut endoderm to respond to signals 




from cardiac mesoderm, followed by the induction of liver-specific gene 
expression. 
A main question in gut organogenesis is if there are present different domains 
of developmental competence in the endoderm that decided where different 
tissues could arise. Such a domain competence could be due to differential 
expression of transcription factors or signal-transduction molecules along the 
antero-posterior axis in the endoderm. There is some evidence for a domain 
of competence for liver formation and there is significant importance of 
transcription factors in establishing the endodermal domain that gives rise to 
liver. Three highly related FoxA (forkhead box A) proteins, are expressed in 
the fetal and adult liver as well as other endoderm-derived tissues. The FoxA 
pro- teins regulate almost all liver-specific genes as well as genes in the lung 
and pancreas (Zaret, 1999). The FOXA (HNF3) proteins were first discovered 
by their ability to bind to the promoters of the genes encoding α-1-antytrypsin 
(A1AT) and transthyretin (TTR) (Kaestner et al., 1999). In the endoderm, the 
beginning of FoxA gene expression precedes the induction of the hepatic 
program by FGFs signals. Expression of FoxA2 (formerly Hnf3β) starts in the 
primitive streak during gastrulation. FoxA1 (Hnf3α) (Sasaki and Hogan, 
1993) expression initiates in the gut endoderm at E7-E8, before 
organogenesis, whereas FoxA3 (Hnf3γ) expression begins in the gut 
endoderm at E8-E9 but is restricted to the midgut and hindgut regions (Ang et 
al., 1993, Monaghan et al., 1993). FoxA1 and FoxA3 genes are also 
expressed in early neural tissues (ectoderm) and in the notochord 
(mesoderm), but all FoxA genes are restricted to the endoderm-derived 
organs in adults (Lai et al., 1991). 




Among the transcription factors found to be expressed in the definitive 
endoderm, the transcription factors Hnf3β and Gata4 have each been found to 
act as mediators of competence in the foregut endoderm (Kaestner et al., 
1999). In vivo footprinting analyses of the albumin enhancer in E9.5 mouse 
liver buds revealed that several binding sites, including Hnf3β, Gata4 and Nf-
1 sites, were occupied. In contrast, extracts from the gut endoderm, a tissue 
capable to follow a hepatic fate but uncommitted and not expressing albumin, 
showed in this same assay that only Hnf3β and Gata4 sites were occupied 
(Gualdi et al., 1996, Bossard and Zaret, 1998). Hnf3β and Gata4 are able to 
bind silent hepatic enhancers and mark them as possessing the potential to be 
expressed following induction.  
Other transcription factors involved in early stages of liver development are 
Hex and Prox1. Hex encodes a homeobox transcription factor; which is 
essential for very early aspects of hepatic development and which is amongst 
the earliest markers of developing liver. Hex mRNA at E8.5 is restricted to 
two distinct regions within the ventral endoderm, the future sites of the liver 
and thyroid (Keng et al., 1998). Knockout experiments have also revealed a 
role of the second homeobox transcription factor called Prox1 during early 
stages of hepatic development (Oliver et al., 1993).  
1.4.1 Transcriptional regulation of hepatic maturation 
During the 1980s a huge effort by many labs allowed the identification of 
transcription factors that bound transcriptional regulatory elements of genes 
that are predominantly expressed in the liver (Lai et al., 1991). Among liver- 
specific transcription factors possessing various structural motives are 
homeodomain proteins HNF1α and HNF1β, the winged helix proteins 




FOXA1, FOXA2, and FOXA3, the leucine zipper proteins C/EBPα and β, the 
orphan nuclear receptor HNF4α and the onecut protein HNF6. Disturbance of 
some genes does have serious consequences on liver function. Additionally, 
although fetal livers develop normally, hepatocyte proliferation was 
decreased in newborn c/ebpα−/− livers (Timchenko et al., 1997). 
Transcription factors cooperate to coordinate gene expression so many 
mutations do not disrupt hepatocyte differentiation. The majority of 
promoters are bound by multiple factors and, therefore, it seems that loss of a 
specific factor can be compensated for by other transcription factors present 
within the cell. As this model may be generally applicable it has been 
confirmed that during development of the fetal liver the nuclear hormone 
receptor, Hnf4α, is crucial for expression of a large array of genes that define 
hepatocyte function (Li et al., 2000). Hnf4α acts as an essential regulator of 
hepatocyte differentiation. Hnf1α transcriptional regulatory elements possess 
the Hnf4α binding site. Hnf4α controls hepatocyte differentiation through the 
activation of a cascade of transcription factors that eventually define the gene 
expression profile of the mature hepatocytes. Hnf4α−/− embryos arrest during 
gastrulation, prior the start of hepatogenesis, because of defects in visceral 
endoderm function (Duncan et al., 1997). The combined application of 
molecular genetics, molecular biology and embryology led us to slowly 
understand of the mechanisms that control hepatogenesis. 
1.5 Hepatogenesis in vitro  
The microenvironment of establishing hepatocytes is a consistently 
modifying process of successively occurring biological events (Duncan, 
2003a). Every stage of cell development and differentiation is firmly 




regulated by intra and extracellular contact along with cell independent 
mechanisms. Liver development is controlled by several distinctive paracrine 
factors. The critical role was assigned to transcription factors and cytokines, 
which have been documented as important molecules during the key steps of 
the liver development. NODAL (Activin A), FGFs, BMP, HGF and OSM are 
herein the most essential extracellular signals (Borrello et al., 1992, Duncan, 
2000, 2003a). At the intracellular stage, the liver enriched transcription 
factors like hepatocyte nuclear factor ((HNF)3α, β), HNF4α, HNF1α, β, 
HNF6, and CCAAT enhancer binding protein ((C/EBP)α, β) act at particular 
developmental phases in order to control liver-specific gene expression 
(Kyrmizi et al., 2006). 
In theory, experimental conditions have been applied to induce cultured 
pluripotent human ES cells into functional hepatocytes, are based on 
reconstructing the in vivo microenvironment. They used the supplement of 
soluble medium factors and reconstruction of cell-matrix and cell-cell 
interactions. Overexpression of liver-enriched transcription factors (LETF) 
genes can be an alternative, but has the limitations. 
 1.6 Induction of hepatic cell fate via supplement of soluble factors 
cytokines, growth factors, hormones) 
The use of growth factors and cytokines is essential for human ES cells 
differentiation into hepatocyte-like cell in vitro. Hormones and corticosteroids 
relatively perform a supporting role. 
The development of endoderm shows an important part of initiating the early 
stages of liver development. Two situations are required to stimulate 




approximately 70- 80% of definitive endoderm from human ES cells: 
signaling by Activin A/NODAL ligands and release from inhibitory signals 
produced by PI3K through insulin (D'Amour et al., 2005). Primarily, Activin 
A enriches human ES cell culture for definitive endoderm. FGFs and BMPs, 
are effective in mediating early hepatic differentiation. HGF supports mid-
late hepatic phenotype (e.g. ALB expression) (Kumashiro et al., 2005) but do 
not induce functional maturation. Stepwise supplement of FGF, HGF and a 
combination of insulin-transferrin-sodium selenite (ITS), dexamethasone and 
OSM was successful. Additional variations of the last consecutive approach 
also result in 70-80% purity of ES-derived hepatocytes within the culture 
system(Agarwal et al., 2008). Inseparable aspect of most differentiation 
protocols is the co-exposure to serum, which includes hormones, growth 
factors and other undefined substances that will influence the stochastic 
differentiation of pluripotent ES cells (Jochheim et al., 2004). Recently many 
efforts have been made to function under serum-free conditions (Hay et al., 
2008a,b).  
1.7 Hypothesis 
No studies have yet to classify and characterize the genetic and phenotypic 
mechanisms in developing human fetal liver. The unique access for us to 
isolate the human fetal liver has given an edge over to study the insights of 
the developing human fetal liver. We can identify the key regulatory 
mechanism that regulate during the liver development. 
By identifying the key transcriptional factors, growth factors and extra 
cellular matrix in developing human fetal liver we can manipulate them in 




vitro for ideal cell culture for differentiating the functional hepatocytes. The 
ability to understand the human fetal development gives clues to maintain and 
expand the cells in vitro and control differentiation. These cells can be further 
transplanted into the cirrhotic liver for principle proof of survival




1.8 Aim of the study 
To understand the key regulatory mechanisms of developing human fetal liver 
during mid-gestation period of organogenesis 
Sub aim 
1. To determine the regulatory factors that control epithelial and 
hepatocytic specification during development. 
a. To determine the regulatory mechanisms of developing fetal 
liver. 
b. To determine the key transcriptional factor, growth factor and 
extracellular matrix. 
2. Establishment of in vitro culture conditions for hepatic differentiation 
and maturation.  
a) To identify the key growth factors for optimal cell culture for 
efficiency of expansion 
b) To optimize the Extracellular matrix for ideal hepatocyte 
culture condition. 
3. Proof of survival efficacy in small and large animal models in acute 
liver failure  

































The core concept of this whole study is to explore the genetic regulation 
during the development of human fetal liver at second trimester. In this 
chapter we mainly describe about the characterization of the developing 
human fetal liver at different gestational stages at second trimester with 
known liver and stem cell specific gene set using PCR array and microarray 
analysis. This chapter also validates the previous studies on fetal liver 
development and also gives us the new understanding about the classification 
of liver development and its phases, which can be used in in vitro 
applications. This key information can be used in to enhance the 
differentiation and maturation of hepatocytes in vitro.  
During gastrulation, the endoderm germ layer is formed, which is further 
divided into foregut, midgut and hindgut regions. In recent studies using fate-
mapping technique in mouse embryo it was proved that liver originates from 
the ventral foregut endoderm (Tremblay and Zaret, 2005).  The fetal liver 
develops from the foregut endoderm, which the stem cells specify into liver 
lineage as the liver bud is formed at D20 of gestation, induced by FGF2 and 
BMP4 from the cardiac mesoderm (Rossi et al., 2001). Hepatic diverticulum 
is divided into two regions; anterior portion, which give rise to liver, cells and 
posterior portion give rise to extra hepatic cells. The cells derived after 
lineage differentiation to the liver bud are called bipotential hepatoblast cells 
during development (Tanaka et al., 2009). These bipotential hepatoblasts 
undergo rapid expansion by eight weeks of gestation, and then they 
differentiate into hepatoblasts or biliary cells. During the liver bud stage, the 
liver development undergoes rapid growth and colonized by hematopoietic 




cells to become the major fetal hematopoietic organ (Christensen et al., 
2004). This hepatocytic development process has been well studied in mice, 
which shows that, at this bipotential stage hepatoblast undergoes specification 
from ED9.5 to 13 and hepatoblast differentiation from ED 14 to hepatocytes 
(Lemaigre, 2003). To further complicate issues, the fetal liver is also the site 
of hematopoiesis at embryonic E7 (Gallacher et al., 2000).  
However, to our knowledge, there are very few systematic serial studies of 
developing human fetal liver on human fetal liver with both genomic and 
phenotypic analyses. The gene expression changes in this second trimester 
study will provide us knowledge for manipulating the microenvironment or 
reprogramming non-hepatic cells to give rise to functional liver cells in vitro. 
In order to determine the systematic development of human fetal liver during 
second trimester, and to identify the key genes that are regulated, we 
characterized the gene expression changes at the following gestational stages 
namely 10 weeks (10 to 11 weeks), 14 weeks (14 to 17 weeks), 18 weeks (17 
to 19 weeks), 22 weeks (21 to 24 weeks) by both full-genome microarray 
analysis and next generation RNA sequencing. The comparison was made 
with the human adult liver. In addition, to validate this study, qRT-PCR array 
was performed for 364 known genes expressed in the liver. To understand the 
phenotypic changes, the temporal expression pattern was examined by 
immunohistochemistry and histology. 
2.2 Materials and Methods 




2.2.1 Source and isolation of human fetal liver cells  
Human fetal livers were obtained from the KK women and children’s hospital 
Singapore and at the National University Hospital of Singapore in accordance 
to the protocol approved by the institutional review board of both National 
University of Singapore and KK hospital. Written informed consent from the 
donor or the next of kin was obtained for use of all samples used in this study. 
Fetal liver was freshly isolated and transported immediately to the laboratory 
for processing in DMEM basal medium (Life technologies Catalog 
number: 11965-092). Primary fetal liver cells were raised and kept in culture 
using the Fetal Hepatocyte medium (CSHFM) as previously described 
(Lazaro et al., 2003, Dan et al., 2006). 








10 weeks 3 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
14 weeks 3 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
17 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
18 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
19 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
21 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
22 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 




23 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
Adult liver 5 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
 
The samples were selected based time frame of the collection and based on 
the quality of the RNA.  
2.2.2 Immunohistochemistry and Immunofluorescence  
All the liver tissue was processed fresh. Sections for Immunofluorescence 
were fixed with 10% cold formalin. Slides for Immunohistochemistry were 
fixed with 1:1 volume mixture of -20’C acetone followed by 0.3% H2O2 to 
block endogenous peroxides. Sections were then blocked with appropriate 
serum 10% for 30 minutes. For immunohistochemistry, the slides were de-
paraffinized by immersing them zs1in 3 changes of Xylene for 5min each. 
This was followed by immersing the slides in a graded series of ethanol and 
finally washed thoroughly in deionized water. For antigen retrieval, tissues 
were incubated with Antigen retrival solution (Dako) for 20min at 37oC. The 
sections were placed in a jar containing DAB solution and incubated until a 
brown color developed. 
Immunofluorescence methodology: Formalin Fixed frozen tissue sections 
were washed in PBS and blocked with 5% normal goat serum at room 
temperature for 1h. A primary antibody cocktail (1:100) was prepared in PBS. 
Tissue sections were incubated with the antibody overnight at 4
o
C. The 
following day, tissue sections were washed in PBS and incubated with a 
secondary antibody cocktail of Alexa Fluor® 488 (1:1000) or Alexa Fluor® 




594 (1:1000) for 1h. After this, the sections were washed in PBS and 
incubated with DAPI (1:2000) to stain the nucleus. The sections were washed 
with PBS and mounted in fluorescent mounting medium. The slides were 
protected from light and later viewed under a confocal laser-scanning 
microscope (Model Fluoview FV- 1000, Olympus Optical Co., Tokyo, 
Japan). Positive cells was determined by manual counting of positive 
immunofluorescent cells to DAPI positive nucleus in 3 separate random fields 
(at 40X magnification objective) on the Olympus microscope. 
Primary antibodies against human antigens were applied to slides for 
overnight at 4 degrees and they include anti-albumin (ICN Pharmaceuticals, 
Aurora, OH), -fetoprotein, vimentin, smooth muscle actin (Dako 
Cytomation, Inc.,Carpinteria, CA),  CD44, CD133 (abcam),  CD45 
(biolegend) EPCAM (novus ResearchProducts, littleton, CO), CK19 
(Amersham, Buckinghamshire, England). For Immunohistochemistry, 
Horseradishperoxidase–conjugated anti-mouse, anti-rabbit and anti-goat 
antibodies (all from Vector laboratories, Burlingame, CA) served as 
secondary antibodies with positive detection based on reaction with 3,3-
diaminobenzidine tetra hydrochloride. Fluorescent detection was by Alexa 
Fluor® 488 or Alexa Fluor® 594 conjugated secondary antibodies 
(Invitrogen, Carlsbad,CA).  
2.2.3 RNA isolation 
Total RNA was isolated using Trizol reagent (Invitrogen, Austin, TX Catalog 
number: 15596-026), 10 week, 14week, 18 week, 22 week and human adult 




liver. Isolated RNA was subjected to bioanalyser to check the integrity and 
used which was more than 8 in all our experiments.  
Materials and instrument 
Trizol reagent (Invitrogen, Austin, TX Catalog number: 15596-026) 70% 
ethanol  β-mercaptoethanol  Spectrophotometer (Nanodrop; Model No. 
ND1000, Thermo Scientific, MA, USA) 
Procedure 
HOMOGENIZATION: Clean Polytron homogenizer with RNzap, then wash 
with EtOH,  dH2O and finally with 1 ml of Trizol reagent (every time run 
Polytron at full speed for about a minute). Add 500ul Trizol into a 5ml tube. 
Transfer freshly isolated liver tisues to an eppendorf tube, Add with Trizol 
(500ul), pool together to bring the volume to 1ml total. 
Phase separation: Shake the homogenate for 10 minutes at RT to permit the 
complete dissociation of nucleoprotein complexes. Supplement the 
homogenate with 0.2ml of chloroform per 1 ml of Trizol, cover the samples 
tightly and shake vigorously (vortex) for 15 seconds. Incubate the mixture at 
RT for at least 10 minutes (up to 30 min). Centrifuge at 14, 000g for 15 
minutes at 4
o
C. Following centrifugation, the   mixture separates into a lower 
red phenol-chloroform phase, interphase and the colorless upper aqueous 
phase. RNA remains exclusively in the aqueous phase whereas DNA and 
proteins are in the interphase and organic phase. The volume of the aqueous 
phase is about 60% of the volume of Trizol used for homogenization. Add 
isopropanol and the high salt solution (0.8 M Sodium Citrate, 1.2 M NaCl), 




each at one half volume of the aqueous phase. Keep samples at –20 oC O/N 
(or at least 1 h). Centrifuge at 14, 000g for 30 minutes at 4 oC.  
RNA wash and solubilization: Discard the supernatant. Wash 2x with 1.0 
ml of 75% ethanol per 1ml TRIzol used for the initial homogenization. 
Vortex, then spin down at 7, 500 rpm/5 minutes at RT. Remove ETOH. Let 
RNA pellet briefly dry. Dissolve in 20-30ul diH2O Depending on the 
amounts, the resultant total RNA may be subjected to further clean-up with 
Qiagen RNEasy columns. However, it is not recommended if we use get less 
than 10 ug of total RNA (expect 20-40 % loss from the clean-up).  Quality 
controls using Agilent Bioanalyzer. 
2.2.4Qualitative Real Time - PCR Array 
We have used a set of known liver genes that were described in previous 
studies. We customised the PCR array with 364 genes in 4 different plates. 
These plates were classified as 1. liver and stem cell genes, 2. Growth factors 
and 3. Extracellular matrix. These customised plates were manufactured by 
sabiosciences. 
Principle 
Quantitative real time RT-PCR (qRTPCR) is used to amplify a certain region 
of cDNA using forward and reverse oligonucleotides (primers) specific to 
that region. The amplified double-stranded DNA is quantified by measuring 
the amount of fluorescence dye, such as SYBR green, that intercalates with 
the DNA. 
Firstly, the two strands of DNA are separated to form two template strands by 




heating at a high temperature for a brief period of time. This is followed by 
amplification process during which the primers bind to the template strands 
and the enzyme, taq DNA polymerase extends the specific region of template 
DNA. The primers are designed such that they are complementary only to one 
specific region of the DNA which represents a particular gene of interest. 
Each amplification cycle has alternating temperature to allow the sequential 
process of primer binding, extension and denaturation. After several cycles of 
amplification, adequate copies of cDNA are made. 
During the amplification process, SYBR green fluorescence dye intercalates 
with double stranded DNA and the qRTPCR instrument quantifies the 
fluorescence intensity of the intercalated dye and provides a numerical value 
called the cycle threshold (Ct) value (Bustin 2000). The 2
-[ΔΔCt] 
method is 
used to calculate the relative expression of a particular gene in experimental 
groups when compared with control groups (Livak and Schmittgen 2001). 
25mg of RNA were reverse transcribed (SABiosciences first strand kit 
Catolgue No - 330421), and PCR array was performed with 364 genes that 
were divided into four different 96 well plates. This was used to determine 
expression of several genes using specific primer pairs. 
2.2.5 Illumina microarray analysis 
Once we have classified the known set of liver genes, we then probed for the 
high throughput gene analysis.  
Principle of microarray experiment 
A microarray experiment is performed to identify gene expression changes on 




a high-throughput basis. This procedure involves the basic principle of 
nucleic acid hybridization. A microarray chip is made up of thousands of 
oligonucleotides attached onto a solid surface. RNA is extracted from the 
sample to be profiled and converted to cDNA by reverse transcription. The 
cDNA is converted to cRNA by in vitro transcription with fluorescence or 
biotin tags. The biotin-labeled cRNA is spotted on the microarray chip for 
hybridization for a certain period of time and the non-hybridized cRNA is 
washed away. Finally, the microarray chip is scanned under laser light and 
the images obtained are analyzed (Heller 2002; Murphy 2002). 
2.2.5.1 Sample amplification and hybridization 
RNA (500ng) was amplified using the Illumina Total Prep RNA 
Amplification Kit, according to manufacturer’s instructions. cRNA was 
hybridized to Illumina Human Sentrix-6 bead chips Ver.2, according to 
standard Illumina protocols (http://www.illumina.com). 
2.2.5.2 Raw data curation and normalization of Illumina microarray 
Chips scans were processed using Illumina BeadScan and BeadStudio 
software packages and summarized data was generated in BeadStudio 
(version 3.1). The summarized data from BeadStudio was imported into 
R/BioConductor using the read Bead function from the Bead Explorer 
package Background adjustment and quintile normalization was performed 
using algorithms within the Illumine package (function: bg. adjust and 
normalize. quintiles). The normalized data was exported out off 
R/BioConductor with write. BeadData function. 




2.2.5.3 Normalization and statistical analysis of Illumina microarray data 
All microarray experiments were conducted in biological triplicate. A gene 
was considered detected if the average detection score (p-value) of the three 
replicates was less than 0.05.  Quintile normalization and statistic calculations 
were carried out using the Partek software. 
2.2.6 Next generation sequencing data 
Our analysis from PCR array and Microarray data showed different phases in 
liver development (Discussed later in the chapter). We need an advanced tool 
to analyze the important genetic differences at each stage. Although 
microarray provided us a large amount of data the limitation of using the 
denominator of genes greater than 2 fold restrict us to existing genomic 
sequencing information. RNA-seq experiments on the other hand work well 
for investigating both known transcripts and exploring new ones. Therefore, 
RNA-seq is ideal for discovery-based experiments. And while microarrays 
are limited to the reference information available during production, RNA-
seq experiments may be updated as new sequence information is obtained.  
Second, RNA-seq delivers low background signal. This is because DNA 
sequences can be unambiguously mapped to unique regions of the genome. 
As a result, noise in the experiment is easily eliminated during analysis. 
Hybridization issues seen with microarrays, such as cross-hybridization or 
non-ideal hybridization kinetics, are also eliminated in RNA-seq experiments. 
This offers another signal-to-noise advantage. 
 Finally, RNA-seq has the ability to quantify a large dynamic range of 
expression levels, with absolute rather than relative values. Even with 




organisms lacking a reference genome, de novo transcriptome assembly and 
differential expression analysis can be performed. There is no upper limit for 
this quantification, and at Cofactor, we can help you to determine the number 
of reads you need to find the information you’re looking for with high levels 
of reproducibility between both technical and biological replicates.  
For the next generation RNA sequencing data, we isolated RNA from the 
tissue samples determined the RIN number and passed on to our collaborator 
in Genome Institute of Singapore for the sequencing. 
Results: 
2.3 Liver architecture – Hepatic portal vein  
The light microscopic images of H&E show the cellular architecture of liver.  
In our observation of H&E on the human fetal liver, the ductal plate appeared 
small and distinctly differentiable from the late stages at 14w and became 
more organized with portal mesenchyme during 18w. We notice that by 22 
weeks, portal triads are formed and are surrounded by hepatocytes, which are 
arranged in single cell sheets known as hepatic plates, separated by sinusoid 
spaces that are connected to a network of blood vessels (capillaries) (Figure 
2.1).  
2.4 Phenotypic characterization 
To determine the different types of cells present in the developing human 
liver, we characterized the phenotypic pattern at each stage with 
Immunohistochemistry using different markers namely Epithelial cell 
adhesion molecule (EpCAM), Vimentin, Smooth muscle actin (SMA), Alpha 




feta protein (AFP), CD133 (PROMININ 1), CD45, Albumin and cytokeratin-
19 (CK-19) on each time points. These markers are classified in different cell 
types and play vital functions during the fetal liver development. 
Table 2: Markers involved in fetal liver development 
2.4.1 EpCAM 
EpCAM is a cell-surface glycoprotein expressed on cholangiocytes, but the 
expression on matured hepatocytes is diminished in adult liver (de Boer et al., 
1999). It was also reported that multipotent progenitor cells derived from 
human fetal liver expressing EpCAM (Dan et al., 2006). EpCAM also serves 
as a useful marker to track the hepatic differentiation, as it is expressed in the 
progenitor cells cytoplasm and is lost in the adult hepatocytes (Rao et al., 
2008). 
 The expression profile of EpCAM during human liver development was 
investigated by immunohistochemistry. EpCAM cells were markedly highly 
expressed and localized mainly around the ductal plate area of 10-week liver, 
EpCAM Epithelial stem cell  
CD133 Stem cell marker 
CD44 Stem cell marker 
CD45 Hematopoietic stem cell marker 
Albumin Hepatocyte marker 
AFP Fetal hepatoblast marker 
Vimentin  Mesenchymal marker 
SMA myofibroblast marker 
CK19 Liver progenitor cell  




confirming the presence of liver progenitor cells and corroborating with 
suggestion from previous studies done by Schelmz. At 14 weeks, more 
EpCAM positive cells were surrounded around the portal tracts and spread 
along the parenchyma of the liver. Interestingly, the expression of EpCAM 
expression is decreased during week 18, and upregulated in expression at 22 
gestational weeks of the developing liver. (Figure 2.2 and Figure 2.3)  
2.4.2 CD133 and CD44 
The expression profiles of CD133 and CD44 marker for the liver specific 
stem cells were studied by immunohistochemistry.  The expression of CD44 
increased in week 10 and decreased at 14 and 18 weeks of the fetal liver. 
Then notably, there is second wave of CD44 and CD133 colabelled cells 
expression during the later phase in 22 weeks of fetal liver development. 
These data indicated the presence of liver specific stem cells during the early 
fetal liver development and a resurge in their regulation in later stages of liver 
development. (Figure 2.4 and Figure 2.5) 
2.4.3 CD45: hematopoietic stem cell marker 
Several varieties of stem cells, including mesenchymal stem cells and 
hematopoietic stem cells are found in the bone marrow. The CD45 marker is 
used to distinguish all hematopoietic stem cells for isolation and to grow as a 
homologous population (Shivtiel et al., 2008). 
To understand hematopoietic expression during human fetal liver 
development, we co-labeled the slides with EpCAM and CD45 markers. The 
result distinguishes liver cells from hematopoietic stem cells. The cells, which 




were stained for CD45, were not co-localized with EpCAM suggesting that 
these two markers were independently expressed. This expression pattern 
concludes that the hematopoietic stem cells are present in the developing 
liver. We observed that during fetal liver development, the number of CD45-
positive cells displayed an interesting pattern – only peaking at 18 weeks, but 
remaining low at all other stages. These results coincide with the change in 
microenvironment niche of the liver that is conducive to hepatogenesis 
(Figure 2.6). 
2.4.4 Albumin, AFP and KRT19  
AFP is the most abundant plasma protein found in the human fetus. The 
expression of AFP has been reported to be decrease after birth where they 
begin its decrease prenatally (Jones et al., 2001). The differentiation of bi-
potential hepatoblast into hepatocytes or Billiary epithelial cells (BEC) begins 
around E13 of mouse development. Initially hepatoblast express genes 
associated with both adult hepatocytes (Albumin) and BECs (cytokeratin-19), 
as well as in fetal liver genes such as α-fetoprotein (AFP).  
The expression of AFP is interesting – we noticed a homogeneous expression 
at week 10 and an increase in the expression at week 14, which is believed to 
be the hepatoblast specification phase. AFP expression begins to decrease at 
week 18 and we notice a striking decrease in the expression at week 22. In 
contrast, the expression of albumin begins to steadily increase as the liver 
develops and we notice high expression of albumin cells at week 22 (Figure 
2.7). The same expression pattern has been previously reported in rat liver 
during prenatal (17 to 21 days of gestation) and postnatal periods (1 to 5 
weeks old neonates) (Poliard et al., 1986). During fetal stages (from week 14 




up to week 18), about 50% of liver cells expressed albumin and AFP. From 
E18 up to birth, the albumin and AFP positive cells are expressed inversely; 
we observed an increase in albumin positive cells and a decrease in AFP 
positive cells, which disappears in adult liver (Figure 2.7).  
KRT19 is a marker for billiary epithelial cells in the duct plate formation 
(Govaere et al., 2014).  We notice the KRT19 cells are incorporated into the 
hepatic mesenchyme to form the biliary duct at week 10. Progressively, these 
cells begin to form as ductal plates at week 18. At 22 weeks, we see the 
formation of ductal plates surrounding the portal vein – an indication of 
maturation towards functional adult liver (Figure 2.8).  
Non parenchymal cells: How is nonparenchyma developed in fetal liver? 
2.4.5 Vimentin and Smooth muscle actin 
We analyzed the distribution of mesenchymal cells in fetal liver parenchyma.  
Here, the parenchymal cells were labeled with anti-Vimentin (mesenchymal 
cell marker) and anti-smooth muscle actins antibodies. The expression of 
Vimentin was distributed evenly throughout the liver development with no 
noticeable difference seen. However, we noticed that the expression of 
smooth muscle actins was increased at the vasculature of the blood vessel 
formation in liver. The formation of the vasculature initiates at around week 
10 and forms an endothelial ring at around week 18. These events result in the 
formation of a blood vasculature at around week 22, leading to the maturation 
of fetal liver cells (Figure 2.9 & Figure 2.10). 
 




2.5 Hierarchical clustering: 
To define the genetically distributed phases in the liver development, total 
RNA was isolated from the human fetal liver samples, as described in the 
materials section. The RNA quality was analyzed with bioanalyser, upon 
which only those RNA samples that the passed the quality with integrity 
number (RIN) above 8 for each fetal liver samples were used for microarray 
analysis. An 8-bead chip Illumina microarray was performed and the raw data 
was analyzed with Partek analysis software. The Hierarchical clustering 
revealed that, adult liver to be in stark contrast with the expression pattern 
seen in all the fetal liver samples of the second trimester. Moreover, within 
the fetal liver samples, 10- and 22-week samples were closely related, as 
compared with 18- and 14-week samples (Figure 2.11). Further, the 
genotypic and phenotypic differences were analyzed to classify the 
differences between these phases with by qRT-PCR and 
immunohistochemistry.  
2.6 Phases in human fetal liver development 
Fetal livers RNA profiles were first subjected to customized qRT-PCR, which 
had genes, previously listed in liver development in animal and human 
models. In addition, the microarray analysis was performed systematically in 
fetal liver samples of various stages of development, in an effort to implicate 
novel genes in the role of fetal liver development in the second trimester. In 
both – qRT-PCR and microarray analyses, the hierarchical clustering revealed 
4 distinct phases based on their expression pattern such as: stem cell 
regulation phase till week 10, hepatoblast proliferation phase at around week 




14, hematopoietic phase at around week 18 and liver maturation phase at 
around week 22.  
The key phenotypic and genotypic profile of each stage was analyzed using 
customized liver and stem cell gene array sets. The list of genes in these array 
sets is described in detail in materials and methods section.  A few important 
genes that are expressed at different stages of fetal liver development are 
summarized in Table 1. 
Table 3: Genes involved in different phases of liver development 
(Classified based on Known liver and stem cell Genes set) 

















































Table 4: Overview of different stages in human liver development 
10 week onwards Stem cell and specification phase 
14 week onwards Specification 




18 week – 22 weeks Hematopoiesis and differentiation 
22 weeks – adult  Maturation and proliferation 
 
2.6.1 Phase 1 (10 week) 
We observed that week 10 specimens were rich in embryonic stem cell 
transcriptional factor markers such as Homeobox Transcriptional factor 
(NANOG), NODAL Growth Differentiation factor, SRY Box2 (SOX2) and 
POU Class 5 Homeobox 1 (OCT4), which corroborates with the liver 
specification profile described in early studies (Figure 2.12). At this stage we 
also noticed that the EpCAM positive cells were strongly expressed at the 
ductal plate area along with a higher number of mesenchymal stem cell 
marker-positive (CD44-positive) cells. These markers corroborate that the 10 
weeks fetal liver is at the early stages of development and rich in stemness. 
We also observed the up regulation of Hepatic nuclear factor 1 (HNF1a) 
transcriptional factor that in literature described as a marker for hepatoblast 
specification (Figure 2.13).  
2.6.2 Phase 2 (10 – 14 weeks) 
Following the embryonic stem cell phase, the expressions of stem cell 
transcriptional factors were relatively reduced as compared to week 10. At 
this stage we do not observe any relative genetic changes compared to 10 
weeks and 18 weeks samples. However, we notice three important markers 
upregulated, which are important for hepatoblast determination. At first, high 
number of AFP (Hepatoblast marker) positive cells was detected at this stage. 
In addition, a sudden surge in CD133 positive cell was observed along with 




the increase in the level of Albumin expression was detected in the later 
stages. 
2.6.3 Phase 3 (17 to 19 weeks) 
It has been well documented that during fetal development, liver acts as a 
hematopoietic organ. In our study, we noticed the expression of CD45-
positive cells (hematopoietic marker) at week 18. 
2.6.3.1 Oncostatin M, TISX and XIST transcriptional factors 
In addition, the expression of hematopoietic stem cell activator X-inactive 
specific transcript (XIST) was also upregulated. We considered this to be the 
hematopoietic phase. However, we also noticed the upregulation of TSIX 
(non-coding RNA gene that is antisense to the XIST RNA) gene. These 
changes at this phase, combined with the increased expression pattern of 
Hepatocyte Growth Factor (HGF), Oncostatin M (OSM) and delta-like 1 
homolog (Drosophila) (DLK1) suggest that the hematopoietic stem cells are 
observed at week 18 of fetal liver development.  
We noticed that the change was obvious with the expression changes with 
Oncostatin M, TISX and XIST. The expression of XIST transcriptional factor 
is believed to be transiently activated in hematopoietic stem cell 
differentiation. However, contrastingly, blocking the reactivation of 
hematopoietic stem cells resulted in an increase in the expression of XIST 
repressor factor TIST at week 18. This expression pattern of XIST and TIST 
at around week 18 in fetal liver suggests decrease homeostasis of 
hematopoiesis (Figure 2.14). 




2.6.3.2 HGF: hepatocyte growth factor & Protein delta homolog 1 (Dlk1) 
From the Array data, we observe the gene expression profiles of HGF and 
DLK1 gene were upregulated at around week 18 of fetal liver development. 
We have previously mentioned about the hematopoiesis during the 18 weeks 
period of the liver development, so by analyzing both the results, we believe 
that, when the hematopoietic stem cells secrete factors like OSM, HGF is 
activated to stimulate hepatoblast differentiation. These secreted factors 
induce the liver differentiation into liver maturation phase (Figure 2.15).   
2.6.4 Phase 4 (19 – 24 weeks) 
At the time that hematopoiesis phase is ceasing in liver, to our surprise we 
noted an upsurge in the expression of embryonic stem cell regulators factors 
such as OCT4, SOX2, NANOG, and the expression of KLF4 during the 22 
weeks.  This corresponded with an increase in the expression of CD44, an 
EpCAM progenitor marker. The expression of hepatic-specific transcriptional 
factors Hepatic nuclear Factor 4 (HNF4a), Hepatic nuclear Factor 3 (HNF3) 
and Prospero Homeobox 1 (PROX1) at this stage indicates that the liver 
undergoes maturation. This is surprising, as classically at this stage of liver 
development, hepatoblast differentiates into hepatocytes.  We observed the 
downregualtion of AFP gene at 22 weeks compared to 10 weeks (Figure 
2.16).  In addition, we also noticed the upregulation of EGF while other 
factors OSM and HGF decrease in expression (Figure 2.17).  
At this stage, metabolic markers (CYP genes) begin to surge in expression 
during the week 22 of fetal liver development an indication of maturation 
(Figure 2.18). 





This is the most systematic study yet, on the phenotypic and genotypic 
characterization of human fetal liver development. Temporal analysis of the 
developing fetal liver in second trimester, in this study, showed 4 distinct 
phases that are characterized based on the gene expression profile.  
The expression pattern of EpCAM suggests that, there are distinct phases 
such as that of progenitor cell population surge at 10 weeks; that of 
hepatoblast proliferation from 10 to 14 weeks; hematopoietic phase at 15-18 
weeks; and maturation phase at 22 weeks. This suggests that epithelial cell 
proliferation appears to take a backstage during the hematopoietic phase but 
undergo a second wave of progenitor cell proliferation with resurgence with 
termination of the hematopoietic phase. 
Hematopoietic cells secrete OSM; and the expansion of hematopoietic cells 
results in the increase of the local OSM concentration, which consequently 
promotes hepatic development. In response to OSM, hepatocytes begin to 
acquire liver-specific functions at the expense of hematopoietic activity. 
XIST encodes noncoding transcripts that silence one of the 2 X chromosomes 
through X chromosome imprinting. XIST is considered to be active only at 
the early embryonic stages. The high-level expression of XIST supports the 
notion that XIST is reactivated during early hematopoiesis.  
The termination of the hematopoietic phase can be explained by the 
following: 1) The loss of stromal cell phenotype which is believed to be the 
support cells for hematopoietic stem cells in liver (Kiel and Morrison, 2008). 
2) The Unique expression of XIST and TIST gene at week 18. XIST gene is 




shown to activate in hematopoietic precursor cells (Savarese et al., 2006) and 
TSIX gene is proven antagonist of XIST gene. This genetic imbalance in 
observed in week 18 only. 3) Although DLK and HGF gene are upregulated 
and show they are important in hematopoietic stem cell proliferation, it has 
been also showed that DLK inhibits formation of murine hematopoietic 
progenitors (Ohno et al., 2001). 4) It is shown that OSM supports both 
development of liver and hematopoiesis in the fetus but as hepatic cells 
mature, hepatic cells lose it ability to support hematopoiesis. Hence OSM is 
believed to support heptogenesis (Kamiya et al., 1999). 
In conclusion, we have observed four different phases during the fetal liver 
development: the stem cell regulation phase at week 10; the hepatoblast 
proliferation phase at week 14; and the hematopoietic phase at week 18. At 
around week 22, the liver seemed to enter the maturation and expansion 
phase. Further, we also observed the presecnce of mesoendodermal cell 
















Figure 2.1  H&E – cellular architecture of fetal liver 
The light microscopic images of H&E show the cellular architecture of liver. 
In our analysis of the fetal liver, the ductal plate (arrows) appeared at 14w and 
became more organized with portal mesenchyme (arrows) during 18w. By 22 
weeks, portal triads (arrows) are formed and are surrounded by hepatocytes, 
which are arranged in single cell sheets known as hepatic plates, separated by 

































Figure 2.2 EpCAM expression at week 10 
Immunofluorescence staining was performed on formalin fixed slides from 
developmental stage week 10. Cells (arrows) from week 10 are seen at ductal 









Figure 2.3  EpCAM expression in fetal liver stages 
 Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. EpCAM cells 
were markedly highly expressed and localized mainly around the ductal plate 
area of 10-week liver confirming the presence of liver progenitor cells. From 
14 weeks, more EpCAM positive cells were surrounded around the portal 
tracts and spread along the parenchyma of the liver. The expression of 
EpCAM expression is decreased during week 18, and upregulated in 
expression at 22 gestational weeks of developing liver. (Confocal Image). 











Figure 2.4 Alubumin and CD133 expression in fetal liver stages 
 Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. CD133+ 
(green) albumin+ (red) colabelled cells (arrows) express strongly at week 14 
indicating the presence of hepatic progenitor cells. In contrast at week 18 the 
percentage of CD133+ albumin+ cell populations is reduced, interestingly at 










Figure 2.5 CD44 and AC133 expression in fetal liver stages 
Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. The arrows 
show the CD44 (red) cells strongly express in week 10. These cell number 
dwindle from week 14 to week 18. At week 22-second wave of CD44 cell 











Figure 2.6  EpCAM and CD45 expression in fetal liver stages 
Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. The tissues 
were stained with EpCAM (green) and CD45 (red). Arrows show the CD45+ 
cells strongly express in week 18 and cell number dwindle from week 22 
EpCAM (green) and CD45 (red) positive. It indicates that Hematopoietic 
stem cells highly express during week 18. Interestingly the CD45 cells did not 












Figure 2.7 AFP and Albumin expression in fetal liver stages 
 Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. The 
expression of AFP is interesting such as we notice an homogeneous 
expression at week 10 and increase in the expression at week 14 which is 
believed to be hepatoblast specification phase. AFP expression begins to 
decrease at week 18 and we notice a striking difference of decreased 
expression at week 22. In contrast the expression of Albumin expression 
begins to steadily increase as the liver develops and we notice high 
expression of albumin cells at week 22 
 











Figure 2.8 KRT19 expression in fetal liver stages 
Immunohistochemistry reactions in formalin fixed slides from developmental 
stages week 10, week 14, week 18 and week 22. The KRT 19 is a marker for 
Billiary Epithelial Cells in the duct plate formation (arrows).  We notice the 
KRT 19 cells are incorporated into the hepatic mesenchyme to form the 
biliary duct at week 10. Progressively these cells begin to form as ductal 
plates at week 18. At 22 weeks we see the formation of ductal plates (arrows) 









Figure 2.9 SMA expression in fetal liver stages 
 
Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. During fetal 
stages the smooth muscle vasculature formation begins at week 14 and 
matured cells are developed at week 22. 
 
 





Figure 2.10 Vimentin expression in fetal liver stages 
 
Immunofluorescence staining was performed on formalin fixed slides from 
developmental stages week 10, week 14, week 18 and week 22. During fetal 












Figure 2.11  Hierarchical clustering analysis 
 Hierarchical clustering analysis was performed to group the human fetal liver 
samples. The figure represents the grouping of different stages of fetal liver. 
10 weeks samples are represented as green color. 14 weeks samples are 
represented as light green color. Week 18 is represented as light blue color. 
Week 22 is represented as blue color. Adult liver is represented as red color. 
The fetal samples compared to Embryonic cells stage differentiation show 
distinct different from each other. Week 22 is similar to week 10 during 
development correlating with the second wave of gene expression compared 
to week 10.  
14w 22w 10w 18w    Adult liver 
 






Figure 2.12  mRNA expression of embryonic stem cell factors 
mRNA-expression levels of SOX2, NANOG, NODAL, OCT4 and KLHL1 
embryonic stem cell factors at each developmental stages were measured by 
real-time-PCR array. The comparison was made with adult liver as control to 
show the level of expression. We noted a second wave of embryonic stem 
cells factors upregulated during 22 weeks of liver development. An similar 











Figure 2.13 mRNA-expression levels of HNF1a  
mRNA-expression levels of HNF1a at developmental stages were measured 
by real-time-PCR array. The comparison was made with adult liver as control 
to show the level of expression. We noted HNF1a gene was expressed at 
early stages 10 weeks of gestation indicating its importance in specification 
















Figure 2.14 mRNA-expression levels of OSM, XIST and TISX  
mRNA-expression levels of OSM, XIST and TISX at developmental stages 
were measured by real-time-PCR experiment. cDNA was converted from first 
strand cDNA kit. The expression was normalized with the endogenous 
control of GAPDH. OSM upregulated during week 18 and gradually reduce 
in expression as the liver matures. Interesting XIST (hematopoietic precursor 
cell activator) transcriptional factor was upregulated at week 18, interestingly 
we notices the upregulation of XIST repressor TISX transcriptional factor at 
week 18. 





Figure 2.15 mRNA expression of DLK1 and HGF 
mRNA-expression levels of DLK1 (Hepatoblast marker) and HGF 
(Hepatocyte differentiation factor) factors developmental stages were 
measured by real-time-PCR experiment. cDNA was converted from first 
strand cDNA kit. The expression was normalized with the endogenous 
control of GAPDH. Both DLK1 and HGF were upregulated during 18week of 
the human fetal liver development.  
 
Figure 2.16 mRNA-expression levels of AFP  
Regulation of AFP gradually decreases across the stages of fetal liver 
development indicating the maturation of liver. 





Figure 2.17 mRNA-expression levels of EGF  
mRNA-expression levels of EGF factors developmental stages were 
measured by real-time-PCR experiment. cDNA was converted from first 
strand cDNA kit. The expression was normalized with the endogenous 
control of GAPDH. EGF expression is upregulated during 22 week of the 
human fetal liver development. 
 
Figure 2.18  mRNA-expression levels of metabolic factors 
 mRNA-expression levels of metabolic factors CYP450 genes in 
developmental stages were measured by real-time-PCR experiment. cDNA 
was converted from first strand cDNA kit. The expression was normalized 
with the endogenous control of GAPDH. All these CYP gene markers were 
upregulated during the week 22 of the human fetal liver development. This 
validates that the liver begins to mature at after week 22.





























3.1 Background  
In the previous chapter, we had classified and described different stages in 
human fetal liver development during second trimester. The study that we 
described in our previous chapter was based on the known liver and stem cell 
genes that were based on what has been reported in past research 
publications. To explore if novel genes and pathway may be involved in 
hepatocyte differentiation, we used full-genome arrays (next generation 
sequencing, microarray and PCR array) to identify transcriptional and micro-
environmental factors (growth factors and extracellular factors) that may be 
differentially regulated during stages of the fetal liver development.  
The recent advancement in high throughput genomics profiling give us an 
opportunity to identify key regulatory mechanisms such that it can define 
definite process for example stem cell or specification stage. These are the 
gene expression profiles, which include transcription factors and key 
hepatocytic genes. Gene expression profiling allows identification of genes 
that are differentially expressed between the fetal liver stages and allows the 
identification of unique markers. Understanding the upregulated or 
downregulated genes in fetal liver developmental phases will help us identify 
factors that may potentially play a role in the hepatocyte phenotype and those 
that regulate differentiation towards attainment of hepatic functions. The 
prospect of manipulating these transcription factors offers great potential for 
the transformation of progenitor cells to differentiated hepatic cells in ex vivo 
culture.  




 Current data available in the literature for gene expression profiles in liver 
development has been largely restricted to murine fetal liver or stem cell lines 
in models of liver disease. There is well-documented evidence and reasons to 
believe that the profile of human progenitor cells may be different from 
murine sources (Yu et al., 2010, Lin et al., 2014). A number of research 
groups have published the notable species differences in gene expression (Yu 
et al., 2010, Lin et al., 2014).  
Studies, hitherto, lack detailed examination of various stages of liver 
development; but rather, deal with either detailed genetic or phenotypic 
examination at any one stage of liver development (Yu et al., 2001, Lee et al., 
2012). In contrast, ours is a systematic study of gene expression and 
phenotypic characterisation in developing human fetal liver, using adult 
human liver as comparison. 
Characterisation of genetic profiling of human fetal liver development and the 
maturation process as a high throughput screening of potential novel 
progenitor cell markers and key regulators of hepatocyte differentiation may 
add value to the current information about liver development. Knowledge 
gained from these studies will be critical as the potential for manipulation 
allows us to keep cells in their progenitor stage to achieve maximum 
expansion. Key genes that determine the liver phenotype will also form the 
basis for targets for subsequent attempts at reprogramming one’s own somatic 
cell lineages to functional hepatocytes.  
We hypothesize that comparing the genetic profile between different phases 
would provide clues to the regulatory genes that drive or at least are 




associated with the different stages of liver development.  Newly generated 
information on how new candidate genes fit into the genetic network will 
shed light on the complex regulation of liver development.  
3.2 Materials and Methods 
3.2.1 Source and isolation of human fetal liver cells  
Human fetal livers were obtained from the KK women and children’s hospital 
Singapore and at the National University Hospital of Singapore in accordance 
to the protocol approved by the institutional review board of both National 
university of Singapore and KK hospital (Table I). Written informed consent 
from the donor or the next of kin was obtained for use of all samples used 
within this study. Fetal liver was isolated and transported in DMEM medium.  








10 Weeks 3 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
14 weeks 3 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
17 week 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
18 week 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
19 week 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
21 weeks 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
22 week 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 




23 week 1 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
Adult 5 NGS, Microarray, PCR array 
Immunofluorescence and FACS 
3.2.2 RNA isolation 
Total RNA was isolated using Trizol reagent (Invitrogen, Austin, TX Catalog 
number: 15596-026), 10 week, 14week, 18 week, 22 week and human adult 
liver. Isolated RNA was subjected to bioanalyser to check the integrity and 
used which was more than 8 in all our experiments.  
Materials and instrument: 
Trizol reagent (Invitrogen, Austin, TX Catalog number: 15596-026) 70% 
ethanol β-mercaptoethanol Spectrophotometer (Nanodrop; Model No. 
ND1000, Thermo Scientific, MA, USA) 
Procedure: 
Homogenization: Clean Polytron homogenizer with RNzap, then wash with 
EtOH,  dH2O and finally with 1 ml of Trizol reagent (every time run Polytron 
at full speed for about a minute). Add 500ul Trizol into a 5ml tube. Transfer 
freshly isolated liver tisues to an eppendorf tube, Add with Trizol (500ul), 
pool together to bring the volume to 1ml total. 
Phase separation: Shake the homogenate for 10 minutes at RT to permit the 
complete dissociation of nucleoprotein complexes. Supplement the 
homogenate with 0.2ml of chloroform per 1 ml of Trizol, cover the samples 
tightly and shake vigorously (vortex) for 15 seconds. Incubate the mixture at 
RT for at least 10 minutes (up to 30 min). Centrifuge at 14, 000g for 15 






C. Following centrifugation, the   mixture separates into a lower 
red phenol-chloroform phase, interphase and the colorless upper aqueous 
phase. RNA remains exclusively in the aqueous phase whereas DNA and 
proteins are in the interphase and organic phase. The volume of the aqueous 
phase is about 60% of the volume of Trizol used for homogenization. Add 
isopropanol and the high salt solution (0.8 M Sodium Citrate, 1.2 M NaCl), 
each at one half volume of the aqueous phase. Keep samples at –20 oC O/N 
(or at least 1 h). Centrifuge at 14, 000g for 30 minutes at 4 oC.  
RNA wash and Solubilization: Discard the supernatant. Wash 2x with 1.0 ml 
of 75% ethanol per 1ml TRIzol used for the initial homogenization. Vortex, 
then spin down at 7, 500 rpm/5 minutes at RT. Remove ETOH. Let RNA 
pellet briefly dry. Dissolve in 20-30ul diH2O Depending on the amounts, the 
resultant total RNA may be subjected to further clean-up with Qiagen 
RNEasy columns. However, it is not recommended if we use get less than 10 
ug of total RNA (expect 20-40 % loss from the clean-up).  Quality controls 
using Agilent Bioanalyzer. 
3.2.3 Qualitative Real Time - PCR Array 
We have used a set of known liver genes that were described in previous 
studies. We customised the PCR array with 364 genes in 4 different plates. 
These plates were classified as 1. liver and stem cell genes, 2. Growth factors 
and 3. Extracellular matrix. These customised plates were manufactured by 
sabiosciences. 
Principle 
Quantitative real time RT-PCR (qRTPCR) is used to amplify a certain region 




of cDNA using forward and reverse oligonucleotides (primers) specific to 
that region. The amplified double-stranded DNA is quantified by measuring 
the amount of fluorescence dye, such as SYBR green, that intercalates with 
the DNA. 
Firstly, the two strands of DNA are separated to form two template strands by 
heating at a high temperature for a brief period of time. This is followed by 
amplification process during which the primers bind to the template strands 
and the enzyme, taq DNA polymerase extends the specific region of template 
DNA. The primers are designed such that they are complementary only to one 
specific region of the DNA which represents a particular gene of interest. 
Each amplification cycle has alternating temperature to allow the sequential 
process of primer binding, extension and denaturation. After several cycles of 
amplification, adequate copies of cDNA are made. 
During the amplification process, SYBR green fluorescence dye intercalates 
with double stranded DNA and the qRTPCR instrument quantifies the 
fluorescence intensity of the intercalated dye and provides a numerical value 
called the cycle threshold (Ct) value (Bustin 2000). The 2
-[ΔΔCt] 
method is 
used to calculate the relative expression of a particular gene in experimental 
groups when compared with control groups (Livak and Schmittgen 2001). 
25mg of RNA were reverse transcribed (SABiosciences first strand kit 
Catolgue No - 330421), and PCR array was performed with 364 genes that 
were divided into four different 96 well plates. This was used to determine 
expression of several genes using specific primer pairs. 




3.2.4 Illumina microarray analysis 
Once we have classified the known set of liver genes, we then probed for the 
high throughput gene analysis.  
3.2.4.1 Principle of microarray experiment 
A microarray experiment is performed to identify gene expression changes on 
a high-throughput basis. This procedure involves the basic principle of 
nucleic acid hybridization. A microarray chip is made up of thousands of 
oligonucleotides attached onto a solid surface. RNA is extracted from the 
sample to be profiled and converted to cDNA by reverse transcription. The 
cDNA is converted to cRNA by in vitro transcription with fluorescence or 
biotin tags. The biotin-labeled cRNA is spotted on the microarray chip for 
hybridization for a certain period of time and the non-hybridized cRNA is 
washed away. Finally, the microarray chip is scanned under laser light and 
the images obtained are analyzed (Heller 2002; Murphy 2002). 
3.2.4.2 Sample amplification and hybridization 
RNA (500ng) was amplified using the Illumina Total Prep RNA 
Amplification Kit, according to manufacturer’s instructions. cRNA was 
hybridized to Illumina Human Sentrix-6 bead chips Ver.2, according to 
standard Illumina protocols (http://www.illumina.com). 
3.2.4.3 Raw data curation and normalization of Illumina microarray 
Chips scans were processed using Illumina BeadScan and BeadStudio 
software packages and summarized data was generated in BeadStudio 
(version 3.1). The summarized data from BeadStudio was imported into 
R/BioConductor using the read Bead function from the Bead Explorer 




package Background adjustment and quintile normalization was performed 
using algorithms within the Illumine package (function: bg. adjust and 
normalize. quintiles). The normalized data was exported out off 
R/BioConductor with write. BeadData function. 
3.2.4.4 Normalization and statistical analysis of Illumina microarray data 
All microarray experiments were conducted in biological triplicate. A gene 
was considered detected if the average detection score (p-value) of the three 
replicates was less than 0.05.  Quintile normalization and statistic calculations 
were carried out using the Partek software. 
3.2.5 Next generation sequencing data 
Our analysis from PCR array and Microarray data showed different phases in 
liver development (Discussed later in the chapter). We need an advanced tool 
to analyze the important genetic differences at each stage. Although 
microarray provided us a large amount of data the limitation of using the 
denominator of genes greater that 2 fold restrict us to existing genomic 
sequencing information. RNA-seq experiments on the other hand work well 
for investigating both known transcripts and exploring new ones. Therefore, 
RNA-seq is ideal for discovery-based experiments. And while microarrays 
are limited to the reference information available during production, RNA-
seq experiments may be updated as new sequence information is obtained.  
Second, RNA-seq delivers low background signal. This is because DNA 
sequences can be unambiguously mapped to unique regions of the genome. 
As a result, noise in the experiment is easily eliminated during analysis. 
Hybridization issues seen with microarrays, such as cross-hybridization or 




non-ideal hybridization kinetics, are also eliminated in RNA-seq experiments. 
This offers another signal-to-noise advantage. 
 Finally, RNA-seq has the ability to quantify a large dynamic range of 
expression levels, with absolute rather than relative values. Even with 
organisms lacking a reference genome, de novo transcriptome assembly and 
differential expression analysis can be performed. There is no upper limit for 
this quantification, and at Cofactor, we can help you to determine the number 
of reads you need to find the information you’re looking for with high levels 
of reproducibility between both technical and biological replicates.  
For the next generation RNA sequencing data, we isolated RNA from the 
tissue samples determined the RIN number and passed on to our collaborator 
in Genome Institute of Singapore for the sequencing. 
Results: 
3.3 qRT-PCR array: 
Gene expression was measured across the fetal liver samples, in second 
trimester, with 10 weeks liver sample as control. The genes that are 2-fold 
upregulated were considered significant. Based on our observation, the data is 
presented in three different sections (transcriptional factors, Growth factors 
and Extracellular factors).  
This PCR array study will only validate the genes, associated with previous 
liver development studies. On the other hand, we could determine the 
temporal expression of these specific genes in each of the described phases of 
human fetal liver development. 




3.3.1 Transcriptional factors at different phases of fetal liver from qRT-
PCR array data 
The transcriptional factors studied in our customized PCR array data are 
genes from previous studies on murine liver development. Liver specification 
genes such as HNF1A, HNF1B PROM1 were expectedly highest at 10 weeks 
when the liver bud is formed and is downregulated at 14 week and 18 week 
compared to week 10. Interestingly, several key hepatocyte differentiation 
genes including HNF4α, PROX1 and HNF1B showed a bipolar upregulation 
at week 10 and then gets expressed later at weeks 22 and adult liver, 
corresponding to our observed 2 stage epithelial expansion in the fetal liver. 
Both HNF4α and PROX1 have been shown to be master regulators of novel 
regulator of cell differentiation and morphogenesis during hepatogenesis. 
These are supported by reported work in knock mice, which exhibited 
dramatically reduced expression of multiple hepatocyte genes and hence, very 
defective hepatocyte morphogenesis (Seth et al., 2014). Prox1 ablation in 
hepatic progenitors causes defective hepatocyte specification and increases 
biliary cell commitment. We also observed that C/EBPα and C/EBPb – early 
liver development markers, appear to be down regulated during fetal liver 
development and upregulated in adult liver compared to the week 10 as 
control, again supporting data that the fetal liver is highly immature compared 
to adult liver and the importance of these genes in hepatocyte differentiation 
(Figure 3.1A and Figure 3.2A) (Soriano et al., 1995).  
Along the same vein, we noted the gradual increase in GATA 4-6 gene 
expression during liver development compared to stage week 10, underlying 




their key roles in liver development. We also looked at nuclear signals that 
have been reported to be highly conserved in organogenesis in multiple 
species. Comparing the various SMAD genes, we noticed that SMAD 5 was 
significantly upregulated at week 10 and significantly downregulated 
throughout the liver development at each of the other time points. In contrast, 
SMAD 3 had an upward trend of gradually increasing in gene expression 
from week 14 till adult liver compared to week 10.  The roles of these 
SMADs have not been fully elucidated in hepatogenesis and offer a potential 
regulatory pathway of upstream TGFbeta signaling in liver progenitor cell 
specification (Figure 3.1B and Figure 3.2B). 
3.3.2 Growth factors from qRT-PCR array data 
Significantly BMP 2 expressions were highly upregulated at week 14 
compared to week 10. It has been previously reported that BMP2 determines 
hepatic vs. pancreatic fate (Won Suk Chung et al., 2008). We noticed an 
upregulation of BMP1 gene at adult liver compared to week 10 (Figure 
3.3A).  
We noticed that FGF genes were comparatively downregulated in fetal liver 
stages compared to week 10 with the exception of FGF1. FGF1 was highly 
upregulated at week 14 compared to week 10 and had a downward trend in 
gene expression during liver development, suggesting a potential association 
with hepatoblast differentiation and amplification. Interestingly we noticed 
the upregulation of FGF4 in adult liver compared to week 10. It was shown in 
previous studies that FGF4 is a key regulator of hepatocyte precursor 
differentiation  (Sekhon et al., 2004) (Figure 3.3B) 




3.3.3 Extra Cellular Matrix 
The specific ECM factors that were differentially regulated were identified as 
Fibronectin, Hyaluronic acid and collagen12A1, which were upregulated at 
14 weeks compared to week 10, suggesting potential for exploitation in 
expanding hepatoblast in vitro. Factors like Lamanin 3 were upregulated at 22 
weeks compared to 10 week raising its possible role in shaping the 
microenvironment niche for proliferation of progenitors at 22 weeks (Figure 
3.4).  
3.4 Next generation sequencing analysis: 
Next generation sequencing was performed to identify the uniquely expressed 
genes at each stages of fetal liver development.  
3.4.1 Genetic categorization of fetal liver and adult liver: 
We analyzed the data with all stages of the fetal liver as one group versus 
adult liver. We observed 518 genes only enriched for fetal liver and 412 
specific for adult liver.  The top 20 genes that were exclusively expressed in 
fetal and adult liver are shown in (Figure 3.5). We proceeded to validate the 
exclusive expression by using RT PCR of AFP gene in fetal liver and 
CYP3A4 in adult liver.  
3.4.2 Expression of transcriptional factors at each stage of fetal liver 
development 
NGS analysis was done and the top transcriptional factors expressed at each 
stage of fetal liver development were identified. From the analysis, we 
observed upregulation of embryonic stage transcriptional factors at week 10 
such as GATA2, HNF4a and SMARCA2 genes. At week 18, genes that were 
upregulated included GLI2 and FOXC1, critical regulators of hematopoietic 
stem cells; HOXD9, E2F1 which have been reported to be involved in liver 




development but remains elusive; and LEF1 involved in T cell development 
(Omatsu et al., 2014; Li Wang et al., 2014; Yu et al., 2012). In week 22 we 
have noticed the upregulation of FOXL1 a hepatic progenitor specific marker 
(Shin et al., 2011). PPARG and STAT3 genes are involved in hepatocyte 
differentiation, along with GATA2, FOS and CREB genes (Ito et al., 2000). 
In corroboration with our PCR array data, the NGS showed upregulation of 
CEBPa/b, HNF4a, GATA1/2/3 and SOX10 expression at adult liver 
validating the importat of these genes in liver maturation (Figure 3.6). 
3.4.3 GO analysis 
Next generation analysis was performed and the genes with p-value less than 
0.05 was used for this analysis. The top 500 genes were identified at each 
stage; these 500 genes were further analyzed and the unique genes for each 
stage were identified and were performed for GO analysis with David GO 
database. The significant signaling pathways that were regulated during each 
stage were analyzed. To categorize the pathways altered during liver 
development, KEGG and GO analysis from DAVID open database was used. 
The genes at each time point were separated into those that were up or down 
regulated relative to the adult liver, and were analyzed separately.  
The functional groups from week 10 till week 18 involved in cell cycle, 
mRNA processing, ribosome activity, cellular homeostasis and MAPKKK 
regulation. In week 22 Pathways were related to mesoderm development, 
regulation of lymphocyte activation, metabolic process, embryonic 
development and Regulation of T cell activation (Figure 3.7).  




The KEGG pathway analysis implicated calcium signaling pathway in week 
10; cell communication, gap junction and long-term potentiation in week 14; 
and hedgehog-signaling pathway in week 18. Interestingly, in week 22 we 
notice hematopoietic cell lineage, hedgehog signaling pathway and renin 
angiotensin system (Figure 3.8).  
3.4.4 Gene atlas  
Gene atlas analysis shows the fetal liver express early erythroid, endothelial 
and fetal liver gene expression, whereas in adult liver, the genes expressed are 
specific to liver only. 
3.5 Liver specific markers  
Many studies have used classical hepatic markers such as albumin and 
SERPINA as surrogate markers for matured hepatocytes. However our data 
suggest that mRNA of both these genes are already upregulated in liver 
progenitors that have yet to fully mature. Along this line, we analyzed for the 
genes that were specific for mature hepatocytes only in the adult liver. RNA-
seq profiles from 16 human tissues from public databases (Figure 3.9) were 
analyzed for Liver specific genes. The final gene list showed 160 highly 
expressed liver-specific genes and identified among these; ALB (albumin) 
and SERPINA1 (Alpha antitrypsin) (Figure 3.10) are listed as examples. 
These 160 liver specific genes that are enriched mainly in complement 
immune system, drug metabolism, CYP450 and serine proteinase inhibitors. 
These genes are highly expressed in adult liver tissues but they may be also 
expressed in fetal immature liver cells and remains highly expressed in 
mature adult liver cells. From our next generation sequencing, we obtained 




top 5% highly expressed genes that are identified in each of these samples 
and mapped them to the 160 liver-specific genes from the public database 
(Figure 3.11). Our data showed ALB is highly expressed in as early as 10-
week old fetal liver; thus, we propose that ALB mRNA as a marker of mature 
hepatocytes be interpreted with caution. We have identified 12 adult liver 
specific genes are highly expressed only in the adult liver samples, namely, 
ORM1, ORM2, APCS, HPX and APOC2 (Figure 3.12), which can be used 
as markers for mature adult hepatocytes. 
3.6 Summary 
1. G0 and KEGG pathway analyses further strengthen our classification of 
mid-trimester liver development into distinct stages and enhance our 
understanding of development.  
2. Key genes that we identified at each time point could serve as potential 
targets for ex vivo manipulation. 
3.7 Interpretation 
Our finding shows that data correlates with the previous findings that have 
describes the liver development in other animals. The transcriptional network 
remains the same in both the human and animal model of fetal liver 
development. However the interesting facts that we highlight in our results 
are the time points that they regulate. HNF4, HNF1 and PROX1, the crucial 
transcriptional factors for the hepatic differentiation, are expressed at 22 
weeks of fetal stage. This is coordinated with other important transcriptional 
factors such as C/EBPa that was earlier believed to suppress hepatoblast 
proliferation high upregulated during maturation stage.  GATA4 gene, that 




which is expressed in early embryonic stages, that which determines the 
hepatic bud formation, is also highly expressed at around week 22. The stem 
cell transcriptional factors such as SOX2, OCT4, NODAL and NANOG are 
upregulated at week 22. These data show that the liver undergoes tremendous 
change at the late stages of development. This could be the key phase that 
will help understand the production of matured functional hepatocytes. 
  




























Figure 3.1 mRNA-expression levels of liver specific transcriptional 
factors 
 mRNA-expression levels of transcriptional factors in developmental stages 
were measured by real-time-PCR experiment. The expression was normalized 
with the endogenous control of GAPDH. A. Liver specific transcriptional 
markers such as HNF1A, HNF1B PROM1 were downregulated at 14 week 
and 18 week compared to week 10. HNF4α, PROX1 and HNF1B showed 
striking difference, which expressed at week 10 and then expresses at later 
weeks 22 and adult liver only. B. We also observed that gradual increase in 
























































Figure 3.2  mRNA-expression levels of liver specific transcriptional 
factors  
 mRNA-expression levels of transcriptional factors in developmental stages 
were measured by real-time-PCR experiment. cDNA was converted from first 
strand cDNA kit. The expression was normalized with the endogenous 
control of GAPDH. A. C/EBPα and CEBPb early liver development markers 
(Soriano et al., 1995) appear to be down regulated during fetal liver 
development and upregulated in adult liver compared to the week 10 as 
control. B. SMAD 5 upregulated at week 10 and significantly downregulated 
throughout the liver development at each time points compared to week 10. In 
Contrast SMAD 3 had an upward trend of gradually increasing in gene 




















































Figure  3.3 mRNA-expression levels of growth factor signaling 
 mRNA-expression levels of growth factor signaling in developmental stages 
14 weeks, 18 weeks, 22 weeks and Adult liver were measured by real-time-
PCR experiment. cDNA was converted from first strand cDNA kit. A. We 
observed BMP gene expression at each stage of liver development. 
Significantly BMP 2 expressions were highly upregulated at week 14 
compared to week 10. Interestingly we noticed an upregulation of BMP1 
gene at adult liver compared to week 10 B. We noticed that FGF genes were 
comparatively downregulated in fetal liver stages compared to week 10. 
FGF1 was highly upregulated at week 14 compared to week 10 and had a 
downward trend in gene expression during liver development. Interestingly 






































Figure 3.4 mRNA-expression levels of extracellular matrix signaling 
 mRNA-expression levels of extracellular matrix signaling in developmental 
stages 14 weeks, 18 weeks, 22 weeks and Adult liver were measured by real-
time-PCR experiment. cDNA was converted from first strand cDNA kit. 
Fibronectin, Hyaluronic acid and collagen12A1, which were upregulated at 
14 weeks compared to week 10. Factors like Lamanin 3 were upregulated 
























































Figure 3.5  Uniquely expressed genes in fetal liver vs. adult liver 
 Uniquely expressed genes in fetal liver vs. adult liver based on relative 
expression in Next Generation RNA sequencing analysis. AFP gene is 














Figure 3.6  Uniquely top 10 expressed transcriptional factors 
 Uniquely top 10 expressed transcriptional factors at each sates were 
represented in this table. At week 10 GATA2, HNF4a and SMARCA2 genes 
were expressed. At week 18 we have noticed the expression GLI2, FOXC1 a 
critical regulator of hematopoietic stem cells, HOXD9, E2F1, FOXL1 
hepatic progenitor bilineage potential gene and LEF1. In week 22 we have 
noticed the expression of transcriptional factors such as FOXL1 a hepatic 
progenitor specific marker, PPARG, STAT3 involved in hepatocyte 
differentiation, GATA2, FOS and CREB genes. Interestingly we have noticed 
the of CEBPa/b, HNF4a, GATA1/2/3, SOX10 and HNF1a expression at adult 
liver validating that the liver maturation. 
 
 
  Fetal Liver 
Adult liver 
  10 weeks 14weeks 18weeks 22weeks 
No of genes 293 217 380 425 906 
      











































) GATA2 NFATC3 FOXC1 GATA2 FOXC1 
HNF4A POU2F2 MEF2A LTF GATA2 
SMARCA2 MEF2A GLI2 STAT3 CACYBP 
    HOXD9 RUNX2 CEBPA 
    NR5A2 PPARG CEBPB 
    RUNX1 NFIA USF2 
    YY1 FOXC1 CRTC3 
    GATA2 SPI1 KLF11 




    E2F1 NR5A2 JUN 
    FOXL1 LEF1 KLF4 
    KLF11 IKZF1 ZNF148 
    POU2F1 FOXL1 NR3C1 
    PITX2 MIR133B NFIA 
    POU1F1 CACYBP PURA 
    KLF4 FOS NR5A2 
    TFAP2A POU2F1 POU2F2 
    ELK1 ZBTB16 ETS1 
    KLF13 CREB1 FOXL1 
    USF2 NFKB1 HMGA1 
    LEF1 POU2F2 PGR 
        ATF2 




Functional clusters specific to week 10  
Term P-value 
Negative regulation of hormone secretion (GO:0046888) 0.004430164 
Blood circulation (GO:0008015) 0.005930383 
glycosphingolipid metabolic process (GO:0006687) 0.009380439 
Mismatch repair (GO:0006298) 0.010567764 
Cell structure disassembly during apoptosis (GO:0006921) 0.011817883 
Apoptotic mitochondrial changes (GO:0008637) 0.011817883 
Regulation of MAPKKK cascade (GO:0043408) 0.012906145 
Muscle contraction (GO:0006936) 0.013263597 
Regulation of protein binding (GO:0043393) 0.014501581 
Glycolipid metabolic process (GO:0006664) 0.014501581 
Positive regulation of MAPKKK cascade (GO:0043410) 0.017421856 
Small GTPase mediated signal transduction (GO:0007264) 0.018296539 
Enzyme linked receptor protein signaling pathway (GO:0007167) 0.023441468 
  
Functional clusters specific to week 14  
Term P-value 
Glycosphingolipid metabolic process (GO:0006687) 0.004641597 
Gamete generation (GO:0007276) 0.005061824 
Spermatogenesis (GO:0007283) 0.003447177 
Cellular cation homeostasis (GO:0030003) 0.009929767 
Glycolipid metabolic process (GO:0006664) 0.007229052 
Ion homeostasis (GO:0050801) 0.025551702 
Cellular homeostasis (GO:0019725) 0.030550563 
Sphingolipid metabolic process (GO:0006665) 0.031267963 
Cellular ion homeostasis (GO:0006873) 0.020256173 
Cellular metal ion homeostasis (GO:0006875) 0.027927012 
Metal ion homeostasis (GO:0055065) 0.03008439 
Membrane lipid metabolic process (GO:0006643) 0.038272107 
Sodium ion transport (GO:0006814) 0.017964263 
Hemostasis (GO:0007599) 0.034002368 
  
Functional clusters specific to week 18  
Term P-value 
Proteoglycan metabolic process (GO:0006029) 0.001885059 
Establishment or maintenance of cell polarity (GO:0007163) 0.032936844 
Glycoprotein metabolic process (GO:0009100) 0.013582578 
Polysaccharide metabolic process (GO:0005976) 0.007053152 
Nucleosome assembly (GO:0006334) 0.040934127 
G2/M transition of mitotic cell cycle (GO:0000086) 0.015231583 
Cell-cell junction organization (GO:0045216) 0.032936844 
Cell-cell junction assembly (GO:0007043) 0.015231583 
 
Functional clusters specific to week 22  
Term P-value 
Cardiac muscle contraction (GO:0060048) 0.001158895 
Steroid catabolic process (GO:0006706) 0.001158895 




Positive regulation of T cell activation (GO:0050870) 0.001669975 
Cardiac muscle tissue morphogenesis (GO:0055008) 0.002366931 
Steroid metabolic process (GO:0008202) 0.002371525 
Regulation of T cell activation (GO:0050863) 0.006008578 
Striated muscle contraction (GO:0006941) 0.007286068 
Lipid catabolic process (GO:0016042) 0.007358378 
L-fucose catabolic process (GO:0042355) 0.010342888 
Regulation of lymphocyte activation (GO:0051249) 0.012563201 
Muscle contraction (GO:0006936) 0.014317794 
Regulation of vasoconstriction (GO:0019229) 0.014396168 
Positive regulation of adaptive immune response (GO:0002821) 0.014396168 
Positive regulation of immune system process (GO:0002684) 0.014895464 
Regulation of muscle contraction (GO:0006937) 0.015743508 
Ventricular cardiac muscle morphogenesis (GO:0055010) 0.016639383 
Fructose metabolic process (GO:0006004) 0.016639383 
Membrane protein ectodomain proteolysis (GO:0006509) 0.016639383 
Steroid biosynthetic process (GO:0006694) 0.016917487 
  
Functional clusters specific to Adult liver  
Term P-value 
Defense response (GO:0006952) 2.41E-06 
Inflammatory response (GO:0006954) 3.30E-05 
Cell-cell signaling (GO:0007267) 6.43E-05 
Cell communication (GO:0007154) 4.56E-05 
Hormone metabolic process (GO:0042445) 1.30E-04 
Response to wounding (GO:0009611) 3.56E-04 
Cell surface receptor linked signal transduction (GO:0007166) 5.66E-04 
Response to external stimulus (GO:0009605) 7.61E-04 
G-protein coupled receptor protein signaling pathway (GO:0007186) 8.01E-04 
locomotory behavior (GO:0007626) 4.71E-04 
Signal transduction (GO:0007165) 6.40E-04 
Chemotaxis (GO:0006935) 7.31E-04 
Anatomical structure development (GO:0048856) 9.29E-04 
Potassium ion transport (GO:0006813) 5.42E-04 
Cellular defense response (GO:0006968) 0.001336351 
 
Figure 3.7  GO Pathway analysis 
 GO Pathway analysis with unique gene list: The functional groups from 
week 10 till week 18 involved in cell cycle, mRNA processing, ribosome 
activity, cellular homeostasis and MAPKKK regulation. In week 22 we have 
noticed were, mesoderm development, regulation of lymphocyte activation, 


















Figure 3.8  KEGG Pathway analysis 
KEGG Pathway analysis with unique gene list: The KEGG pathway analysis 
involve in week 10 calcium signaling pathway, in week 14 cell 
communication, gap junction and long-term potentiation. In week 18 we 
observe hedgehog signaling pathway and in week 22 hematopoietic cell 
lineage, hedgehog signaling pathway and renin angiotensin system. 
Functional pathways analysis specific to week 10 
Term 
HSA04020 CALCIUM SIGNALING PATHWAY 
HSA05040 HUNTINGTONS DISEASE 
 
Functional pathways analysis specific to week 14 
Term 
HSA00603 GLYCOSPHINGOLIPID BIOSYNTHESIS GLOBOSERIES 
HSA04540 GAP JUNCTION 
HSA04916 MELANOGENESIS 
HSA01430 CELL COMMUNICATION 
HSA04720 LONG TERM POTENTIATION 
 
Functional pathways analysis specific to week 18 
Term 
HSA05217 BASAL CELL CARCINOMA 
HSA05222 SMALL CELL LUNG CANCER 
HSA04340 HEDGEHOG SIGNALING PATHWAY 
 
Functional pathways analysis specific to week 22 
Term 
HSA04740 OLFACTORY TRANSDUCTION 
HSA04640 HEMATOPOIETIC CELL LINEAGE 
HSA04660 T CELL RECEPTOR SIGNALING PATHWAY 
HSA04940 TYPE I DIABETES MELLITUS 
HSA04912 GNRH SIGNALING PATHWAY 
HSA04662 B CELL RECEPTOR SIGNALING PATHWAY 
HSA04340 HEDGEHOG SIGNALING PATHWAY 
HSA04650 NATURAL KILLER CELL MEDIATED CYTOTOXICITY 
HSA05010 ALZHEIMERS DISEASE 
HSA04614 RENIN ANGIOTENSIN SYSTEM 
 
Functional pathways analysis specific to adult liver 
Term 
HSA00040 PENTOSE AND GLUCURONATE INTERCONVERSIONS 
HSA00980 METABOLISM OF XENOBIOTICS BY CYTOCHROME 
P450 
HSA00150 ANDROGEN AND ESTROGEN METABOLISM 
HSA00500 STARCH AND SUCROSE METABOLISM 
HSA00860 PORPHYRIN AND CHLOROPHYLL METABOLISM 
HSA04060 CYTOKINE CYTOKINE RECEPTOR INTERACTION 
HSA00120 BILE ACID BIOSYNTHESIS 
HSA00232 CAFFEINE METABOLISM 
 








Figure 3.9  Canonical pathway analyses 
 Canonical pathway analyses for liver specific gene list from public databases 
was compared with our data. The data shows that Albumin and SERPINA 
was the common gene that was upregulated across all stages of fetal liver and 





























Figure 3.10 Albumin and Serpina liver specifc markers 
 Albumin and Serpina liver specifc markers were upregulated in adult liver. 









































Figure 3.11 Top 5 % of liver specific marker 
 A. Top 5 % of liver specific marker from next generation sequencing. B. 
Albumin expressed both in fetal and adult liver. C. ORM1 and APOC2 genes 













Liver specific markers for 
each of the fetal liver stages 
and adult liver sample 








Figure 3.12  A. ORM1, APC5 and APOC2 genes expression 
 Next generation sequencing data shows the upregulation adult liver specific 
ORM1, APC5 and APOC2 genes specific for adult liver and down regulated 




















Figure 3.13 ORM1, APC5 and APOC2 gene expression. A. next 
generation sequencing data shows the upregulation adult liver specific 
ORM1, APC5 and APOC2 genes specific for adult liver and down regulated 
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The major hurdles that have limited the use of human hepatocytes in translational 
medicine, is the lack of a continual and reliable source of cells and the technical 
difficulty in maintaining their differentiated hepatocytic functions in vitro for 
significant periods of time (Leffert et al., 1978). Following liver injury, the 
human hepatocyte exhibits tremendous intrinsic ability to proliferate and 
regenerate itself in vivo (Fausto, 2004). However, despite the rapid advances in 
understanding of the liver anatomy and physiology, it has not been possible to 
proliferate human hepatocytes reliably in culture or prevent them from 
dedifferentiation and losing their hepatocytic functions. 
As a result of these limitations, there have been significant efforts to identify and 
utilize alternative sources of cells that can be expanded easily in culture, and 
subsequently manipulated to give rise to hepatocytes, either by directed 
differentiation (hepatocyte linage stem/ progenitor cells) or transdifferentiation  
(stem cells from other lineages) (Dan and Yeoh, 2008). Candidate cells that have 
been reported to have this potential include embryonic stem cells, hematopoietic 
stem cells, mesenchymal stem cells (MSC) or mesenchymal lineage stem cells, 
hematopoietic stem cells, fetal liver progenitor cells adult liver progenitor cells or 
more recently, induced pluripotent stem cells or reprogrammed somatic cells 
(Dan and Yeoh, 2008).   
Induced pluripotent stem cells or reprogrammed somatic cells are the two leading 
candidates progenitor cells being researched intensively to produce functional 
hepatocytes. While they can, in theory, be easily scaled up and ever improving 




and more efficient hepatocyte differentiation protocols are being reported, the 
current challenges that stand in the way of clinical translation are the ability to 
expand these cells to clinically meaningful numbers as well as their 
differentiation into fully functional hepatocytes.  Gene array studies of 
differentiated hepatocytes from these cells sources show that they are probably 
still at the stage of fetal hepatic side and are quite distant from the full metabolic 
capabilities of adult hepatocytes. 
To overcome these challenges, we felt that identification and thorough 
understanding of the regulatory factors that occur in various stages of the 
physiological fetal liver development would be extremely useful.   
Our overall aim was thus to study the human fetal liver development to identify 
the key mechanisms and potential target genes that can be applied in vitro for the 
expansion, maintenance and maturation of hepatocytes. The results from our 
array data were classified into three categories at each stage of fetal liver 
development are based on their upregulation: (i) Transcriptional factors, (ii) 
Growth factors and (iii) Extracellular matrix (described in detail in chapter 3).  
This chapter summarizes the proof of principle in manipulating genes identified 
in our study in vitro to achieve the intended effect on liver progenitor cells, 
specifically for hepatocyte growth and maintenance.  
Growth factors, extracellular matrix and signaling factors that are significantly up 
regulated at each specific phase, would likely be the putative factors that play a 
key role in the regulation of that phase. 




Based on our observation and gene clustering, we identified different phases in 
liver development. We chose the genes based on these classifications. Week 10-
11 Specification phase - genes at this stage were mostly embryonic stem cell 
factors and would be useful for in vitro iPSC manipulation. Week 14-15: 
Expansion / differentiation phase - Genes at this stage were extracellular matrix 
proteins Collagen, Laminin and Hyaluronic acid. Week 17-19: Hematopoiesis 
and Proliferation Week 20-24: Maturation, EMT phase - genes that were 
upregulated at this stage were SHH signaling, FGF, FGFR and CTGF. Adult 
Liver: functional. 
Specifically, week 11 to 14 would represent the phase of hepatoblast playing the 
role of a transit-amplifying cell in expansion and differentiation into hepatic 
lineage. Similarly, week 19 to 22 would represent the phase of progenitor cell 
proliferation by mesenchymal epithelial transition. Week 23 to adult stage would 
represent the phase of hepatocyte maturation.  
Using this assumption, we identified the following genes from the various classes 
of extracellular matrix, growth factors and signaling factors that are significantly 
up or down regulated (Figure 4.1). We then tested these factors in in vitro 
cultures as modifiable variables in the microenvironment of fetal liver epithelial 
cells to validate the effects. 
 




Table 6: Genetic regulators used in in vitro experiment 
 
4.2 Materials and methods  
4.2.1 Processing of fetal liver cells  
Methods for the isolation and processing of fetal liver cells were modified from 
previously reported protocols (Dan et al., 2006). Fetal liver collected on time of 
call from the hospital range from 10 weeks to 24 weeks of fetal mid-gestational 
stage. Fetal livers were aseptically dissected from the human fetuses under 
hospital environment and maintained in basal medium on ice until use. They are 
transferred to basal medium for transport. To extract fetal liver cells, fetal livers 
were treated with 0.3% collegenase for 15 minutes at 37
o
. Subsequently, the 
livers were triturated with P1000 pipettes to achieve a single cell suspension, and 
10% FBS-containing medium was added to neutralize the collegenase.  The cells 
were pelleted at 700 rpm for 5 minutes, resuspended in the SEGELENS buffer, 
and re-pelleted at 1000 rpm for 3 minutes. The cell pellet was resuspended in 1 
ml of culture medium, and filtered with a cell strainer (40μm pore size). Another 
ml of medium was used to rinse the filter and combined with the cell suspension. 
In average, this process yields 2X10
6 
fetal liver cells in according to the 
gestational age of the fetus (n = 3).  
ECM Collagen, Lamanin and Hyaluronic 
acid 
Growth Factors FGF, FGFR and CTGF 




4.2.2 Culture of fetal liver cells  
The compositions of the culture media studied in this is described in Table 12 
incomplete culture media (DMEM), which were used for the transport of fetal 
liver from KK women and children hospital to the lab; refer to media that were 
not supplemented with insulin, EGF, HGF and OSM. Complete culture media 
included all those factors and were used for the rest of the culture period.  
Table 7: Formulations of the culture media 
Complete medium Concentration Final 
volume 
 
William’s E medium 
(basal medium) 
 450 ml Gibco 
Nicotinamide 10mmol/ml 5 ml Gibco 
HEPES 20mmol/ml 10 ml Gibco 
Dexamethasone 100umol/ml 1 ml Sigma-Aldrich 
ITS+ premix 6.25ug/ml 5ml BD Biosciences 
Sodium bicarbonate 17mmol/ml 10 ml Gibco 
Sodium pyruvate 550mg/ml 5 ml Gibco 
L glutamine 2 mol/ml 5ml Gibco 
Ascorbic Acid 0.2 mmol/ml 5 ml Sigma-Aldrich 
Glucose 14 mmol/ml 12.6 ml Sigma-Aldrich 
Gentamicin (strep/pen) 50ug/ml (5ml) 5ml Sigma-Aldrich 
EGF 20ng/ml 0.5ml BD Biosciences 
FBS 100% 10% Sigma-Aldrich 
4.2.3 Coating culture plates: On day 0 (before the day of culture set-up), 
collagen-working solution was prepared by diluting the stock (3mg/ml) 1:3 with 
sterile water. Tissue culture treated polystyrene plates were coated with the 




collagen working solution at room temperature for overnight in BSII cabinet and 
the next date rinsed with PBS. The wells are stored in 4 degrees until future use.  
The processed fetal liver cells were counted by Trypan Blue exclusion, and 
diluted with the complete culture medium of interest to 2X10
5
cells/ml. This 
suspension was plated onto the collagen-coated plates at desire volume according 




. After 4 hours 
of culture, culture supernatant was removed and the culture wells were rinsed 
with PBS to remove non-adherent cells. Complete culture medium was then 
added to the well. Culture medium was changed every 2 – 3 days thereafter.  
4.2.4 Determining ideal Culture Conditions extra cellular matrix 
To test the ideal ECM obtained for the array data for fetal liver cultures, 
extracellular matrix substrates were studied. Plates were coated with laminin 
(5ug/ml), collagen (1:5), fibronectin (5ug/ml), gelatin (5ug/ml) and hyaluronic 
acid (Suplasyn, Bioniche Life Sciences Inc., London, Ontario, Canada), washed 
with PBS and air-dried in culture hood over night before use.  
4.2.5 In Vitro Differentiation Protocol  
All differentiation protocols were performed in triplicate with freshly isolated 
human fetal liver cells. Basic culture medium was purchased from Gibco / 
Invitrogen (Carlsbard, CA) and supplements were from Sigma Aldrich (St Louis, 
MO).  




4.2.6 Hepatocyte Differentiation  
Cultures were treated with standard hepatocyte culture medium CSHFM 
(Complete described in table 12) and Oncostatin M (OSM) (10ng/mL; R&D 
Systems, Minneapolis, MN) was added as another extra supplement which has 
been proven to differentiate into functional hepatocytic cells. 
4.2.8 Assessment of cell proliferation  
Cell growth was monitored by alamar blue assay. The assay is based on the 
ability of viable, metabolically active cells to intracellular reduce reassuring to 
resorufin and dihydro- resorufin.  The reduction enters cytosol and is converted 
to the reduced form by mitochondrial enzyme activity by accepting electrons 
from NADPH, FADH, FMNH, NADH. It’s then converted to the oxidized (or 
non-fluorescent) blue form to the reduced (fluorescent) red form.   
To perform the alamar blue assay, culture media were removed and the wells 
were rinsed with PBS to remove residual media with phenol red. Subsequently, 1 
ml of alamar blue diluted with OPTI MEM medium was added to each well. . 
The plate was placed in a cell culture incubator for 1 hour. Afterwards, 200μl of 
suspension (in triplicate) from each culture well was transferred to a 96-well 
plate. Optical absorbance was measured in dual mode (at 540 nm with a 
reference at 630 nm) with an ELx808 micro plate reader (BIO-TEK Instruments, 
Winooski, VT).  




4.2.9 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA is the abbreviation of enzyme-linked immunosorbent assay. It is a useful 
and powerful method in estimating ng/ml to pg/ml ordered materials in the 
solution, such as serum, urine, sperm and culture supernatant. The basic principle 
of an ELISA is to use an enzyme to detect the binding of antigen (Ag) antibody 
(Ab). The enzyme converts a colorless substrate (chromogen) to a colored 
product, indicating the presence of Ag:Ab binding. An ELISA can be used to 
detect either the presence of Ags or Abs in a sample, depending on how the test 
is designed.   
Human albumin concentrations from culture media were measured by the 
sandwich enzyme-linked immuno-sorbent assay as previously described. The 
capture antibody (goat anti-human antibody; 4 mg/mL), the detection antibody 
(peroxidase-conjugated goat immunoglobulin G fraction to human albumin; 3 
mg/mL), and the purified human albumin standards were purchased from ICN 
Pharmaceuticals (Durham, NC).  
Results: 
4.3 To evaluate the suitable microenvironment for proliferation human fetal 
liver cells: 
From the array data we identified specific ECM proteins were highly unregulated 
at week 14 compared to 10-week fetal liver sample. Here we would like to 
mention that the 14-week stage was associated with hepatoblast proliferation, in 
which we observed the upregulation in the expression profile of laminin3, 




collagen A2 as well as hyaluronic acid. The expression was significantly reduced 
in the later stages of liver development. Although we have identified these 
specific genes isoforms, we were restricted to use the commercially available 
isoform of these genes for our research. This limitation of unavailability for 
extracellular matrix is one of the hurdles in defining the microenvironment in 
vitro.  We tested each of these ECM individually and in combination to 
determine their effect on fetal hepatoblast culture.  
 To understand the mechanism of action of these variables in in vitro cultures, we 
made careful distinction between the effects of these variables on cell expansion 
and morphology. 
4.3.1 Proliferation: Which is the best Extracellular matrix?  
Cell proliferation was determined by using alamar blue assay. Collagen and 
Collagen/Laminin has the highest adherence but does not promote proliferation. 
Laminin, in combination with collagen, and/or HA, resulted in the highest 
proliferation of fetal liver cells Figure 4.2.   
4.3.2 Effect on expansion 
The cells cultured on collagen only resulted in maintenance of fetal hepatoblast 
morphology. In collagen coated plate, we also observed cells hepatocytes were 
binuclear, which is a typical characteristic of hepatocytes morphology in vivo. 
The cells cultured on a combination of collagen, laminin and Hyaluronic acid 
maintained the immunophenotype but resulted in spindle-type morphology 
(Figure 4.3). The other combinations of these ECM were not as effective as 




Collagen coated plates in maintaining its phenotype. To confirm maintenance of 
cell immunophenotype, we compared morphology with EPCAM and CD44 
immunostaining (Figure 4.4). 
From the results, we conclude that, using combinations of laminin and collagen 
maintains the morphology and proliferation for at least 2 passages.  
4.4 Growth factors 
Growth factors are essential component in every cell culture practice. Every liver 
research group is probing to find a right combination of growth factors to 
maintain, differentiate and expand the hepatocytes in vitro. We are no exceptions 
and from our array analysis we have noticed the upregulation of signaling 
pathways such as FGF and CTGF at week 22 compared to week 10. Our 
hypothesis was to study these signaling factors, which were upregulated at week 
22 (Maturation, EMT phase) in the maintenance and proliferation of liver cells ex 
vivo.  
4.4.1 FGF growth factor signaling 
In our qPCR-array data, the expression of FGF signaling was analyzed by 
comparing the fetal liver stages and adult liver against 10-week as control.  The 
expression of FGF1 was upregulated at 14 weeks s and was down regulated in 
the adult liver, suggesting its importance in the early developmental stages. In 
contrast, the expression of FGF2 was upregulated in adult liver and was down 
regulated in fetal stages. We also observed the expression of FGFR1 which was 
down regulated in adult liver may be associated with matured liver (Figure 4.5).  




We hypothesize that 1) FGF1 may have a role on cell proliferation because it was 
upregulated at 14 weeks. 2) In addition, FGFR1 and FGFR2 receptors 
downregulated at adult liver may have a role in expansion and differentiation.  
Fibroblast developmental factors (FGFs) signaling from the cardiac mesoderm 
induces the liver in the ventral foregut endoderm. During the time of 
hepatogenesis, the cardiogenic mesoderm expresses at least three out of the 
eighteen known FGFs, and the ventral foregut endoderm expresses at least two of 
the four tyrosine kinase FGF receptors (Jung et al., 1999). During the time of 
hepatic induction, the endoderm distinctively expresses FGF receptor 4 (FGFR4) 
(Stark et al., 1991)) and both the endoderm and cardiac mesoderm express FGF 
receptor 1 (FGFR1) (Sugi and Lough, 1995). In situ immunohistochemistry 
studies indicated that FGF1 and FGF2 are generally induced in the cardiac 
mesoderm at the 7-8 somite phases in mouse (Jung et al., 1999). Purified FGF1 
and FGF2 were each found to effectively induce early liver-specific genes within 
the ventral foregut endoderm, when the endoderm was isolated from 2-6 somite 
stages. Studies have demonstrated that FGFs and BMPs are effective in 
mediating early hepatic differentiation. HGF supports mid-late hepatic phenotype 
(e.g. ALB expression) (Kumashiro et al., 2005), but does not induce functional 
maturation. Stepwise supplement of FGF, HGF and a combination of insulin-
transferrin-sodium selenite (ITS), dexamethasone and OSM was successful. 
FGF signaling is one of the most important signaling pathways studied in liver 
development. It is important to mention that FGF growth factors such as FGF1 




and FGF2 have been already determined to be useful in culture medium to 
maintain liver cells.  
The proliferative effect of FGF1 and FGF2 Growth factors on fetal liver culture 
was assessed in vitro by alamar blue staining. Unfortunately, the in vitro effects 
of FGF1 and FGF2 were not congruous with the regulation pattern with our RT-
PCR.  
What was consistent however was that, upon addition of anti FGFR1 and anti 
FGFR2 to block the FGFR1 and FGFR2 receptors in culture, there was 
significant proliferation of liver cells after one month. FGF signaling of the 
various isoforms is believed to be a complex interplay between the isoforms and 
its receptors. In our case, the ratio of FGF and FGFR1 mediates hepatoblast 
proliferation at 14 weeks. This effect is likely complex and does not avail the 
potential for FGF manipulation for ex-vivo expansion or maturation of 
hepatocytes (Figure 4.6 and Figure 4.7).   
4.5 CTGF growth factor 
In our array data we noticed the significant upregulation of CTGF growth factor 
at week 22 fetal liver compared to week 10 (Figure 4.8). Previous studies have 
reported that CTGF (Connective tissue Growth Factor) has a variety of functions 
in developmental biology, which includes angiogenesis, cell adhesion, 
proliferation, skeletal development, tooth development, and apoptosis (Brigstock, 
2003; Perbal et al., 2003; Rachfal and Brigstock, 2005). CTGF has been shown 
to stimulate extra cellular matric (ECM) along with mitogenic and chemotactic 




activities. This indicates that CTGF acts as a central driver in cartilage/bone 
growth and regeneration (Heng et al., 2006; Kanaan et al., 2006; Kubota and 
Takigawa, 2007; Ono et al., 2007). The importance of CTGF in skeletal 
development is demonstrated with the generation of CTGF knockout mice 
(Yamaai et al., 2005). CTGF ablation results in mice with mishappened skeleton, 
craniofacial abnormalities, and defects associated with endochondral ossification, 
and attributes to defects in cell proliferation, matrix formation, and remodeling 
during endochondral ossification. However, the role for CTGF in developmental 
biology of liver is unknown. Our hypothesis is to analyze the importance of this 
growth factor that express at maturation phase week 22 in in vitro liver cell 
culture.  
Effect of CTGF growth factor on human fetal liver culture was studied by adding 
commercially available recombinant CTGF into culture medium. The result show 
that the addition of CTGF has effect on cell proliferation, which has increased 
two folds compared to control without growth factors (Figure 4.9 and Figure 
4.10). In addition to the proliferation effect of the fetal liver cells, we observed 
that the CTGF had no effect on maturation of the cells. The protein assay showed 
the production of serum albumin no increase compared to control cells, 
suggesting that CTGF drives mainly proliferation but not differentiation. 
Limitations and future studies: 
The unavailability of the desired extracellular matrix isoforms – in the future 
studies we need to analyze the effect of these observed isoforms in maintaining 
the liver cells. 








Figure 4.1  Key extracellular matrix in liver development. 
 mRNA-expression levels of ECM proteins Collagen, laminin, and HA were 
measured by real-time-PCR experiment. cDNA was converted from first strand 
cDNA kit. qRT-PCR data shows the upregulation of COL12A1, CTGF, HAS1 










Figure 4.2  Cell proliferation in each well was measured by Alamar Blue dye 
reduction.  
 
Fetal liver cells were plated in culture medium containing 10% FBS with 
different feeder layers. Collagen, lamanin and hyaluronic acid ECM were 
commercially purchased coated on to the pates. The cells were maintained for 6 
days. The cells coated with collagen lamanin were maintained morphologically 
and functionally. With other combinations of EMS the proliferation reduced in 




















Figure 4.3  Extra Cellular matrix.  
Phase contrast images show the morphological changes of fetal liver cells in 
vitro. Fetal liver cells were cultured on different culture conditions for up to two 
passages. A) Collagen B) Combination of HA450, Laminin and Collagen C) 
Collagen and laminin. Cells on collagen plated were maintained morphologically 
even after 2 passages. Combinations with Collagen, laminin and HA50 showed 
morphologically differences and phenotypic changes. 
 
 








Figure 4.4 Phenotypic maintenance  
Immunophenotype of CD44 (green) and Epcam (red) on liver cells cultured for 
15 days in culture. Collagen+lamanin+hyaluronic acid did main the 
immunophenotyping of the fetal cells but the cell morphology was lost in 















Figure 4.5  mRNA-expression levels of FGF signaling pathway was 
measured  
FGF1 was upregulated at 14 weeks suggesting its importance in hepatoblast 
proliferation but was down regulated during adult liver. In contrast, the 
expression of FGF2 was upregulated in adult liver and was down regulated in 
fetal stages. We also observed the expression of FGFR1 which was 











Figure 4.6  Pathway inhibitions by monoclonal antibodies.  
Phase contrast images show the morphological changes of fetal liver cells in 
vitro.  After one month in culture, we observed blocking the FGFR receptors 
maintain the expansion and proliferation of fetal liver cells, whereas addition of 
FGF1 and FGF2 were not effective compared to control. 
  






Figure 4.7  Cell Proliferation Assay.  
Cell proliferation in each well was measured by Alamar Blue dye reduction. 
FGFR1 and FGFR2 maintained the cells while FGF1 reduce in time with culture 
compared to control cells. 
 
Figure 4.8 mRNA-expression levels of CTGF signaling were measured.  
mRNA expression levels of CTGF was measured. CTGF was upregulated at 
week 22. 





Figure 4.9 CTGF effect 
  Phase contrast images show the morphological changes of fetal liver cells in 










Figure 4.10  Cell Proliferation Assay.  
Cell proliferation in each well was measured by Alamar Blue dye reduction. A) 
CTGF recombinant protein addition shows reduction in proliferation Vs. Control. 
CTGF Growth factor has no effect on cell proliferation.












Correlating genetic determinants of liver 





















In our previous chapters, we have elaborated on identifying key transition phases 
of fetal liver development. From our genetic studies, we were able to identify key 
genes that were up regulated at various stages of fetal liver development. We 
further showed that these factors were instrumental in driving and regulating 
hepatoblast proliferation and expansion in vitro. To further validate the 
importance and relevance of these factors, we explored if they were also involved 
in in vivo systems where the ontogeny of liver and its lineages is recapitulated.  
The current model that can replicate the liver progenitor proliferation besides the 
fetal liver is the cirrhotic liver model. This is supported by the work done by Lola 
Reid (Zhang et al., 2008), and has shown that the progenitor cell proliferation in 
liver cirrhosis is symmetrical to fetal liver development. In that study, it was 
described that the liver regenerative process is parallel to those occurring in 
development and involve populations of stem cells and progenitor cells that can 
be identified by anatomic, antigenic, and biochemical profiles (Zhang et al., 
2008). We thus hypothesize that the regulatory signals in fetal liver would be 
recapitulated in the cirrhotic liver.  
To further validate if the same regulatory signals were clinically important and 
relevant in an in vivo stem cell regeneration model, we sought to analyze the 
genetic profile of microenvironment in which human fetal liver progenitor cells 
undergo proliferation, differentiation and maturation, in vivo.  
 




Human adult cirrhotic liver vs. human fetal liver 
We performed PCR gene array analysis for adult cirrhotic liver and compared the 
genes that were up regulated in both the fetal liver and the human adult liver 
versus human cirrhotic liver. We isolated RNA, and qRT-PCR array was 
performed comparing the fresh human cirrhotic liver samples with adult liver and 
fetal liver samples. We tested about 364 genes that were described to be involved 
in liver development by previous studies.  The array data showed an interesting 
trend of cirrhotic liver gene expression was similar to the fetal liver week 22 
during development. The genes that were significantly upregulated in the adult 
cirrhotic liver compared to adult liver sample were stem cell transcriptional 
factors (OCT4, SOX2, NODAL and NANOG), Hedgehog signaling, FGF8, 
BMP3, T (brachury) and HNF1b (Figure 6.1). Therefore this data supports our 
hypothesis of progenitor cell proliferation at week 22. This is evident as the 
upregulation of Stem cell markers.  
5.2 Materials and methods: 
5.2.1 qRT-PCR Array  
Total RNA was isolated using Trizol reagent (Invitrogen, Austin, TX Catalog 
number: 15596-026), 10 week, 14week, 18 week, 22 week, human adult liver and 
cirrhotic liver. Isolated RNA was subjected to bioanalyser to check the integrity 
and used which was more than 8 in all our experiments.  




5.2.2 Immunohistochemistry and Immunofluorescence  
All the liver tissue was processed fresh. Sections for Immunofluorescence were 
fixed with 10% cold formalin. Sections were then blocked with appropriate 
serum 10% for 30 minutes. Primary antibodies against human antigens were 
applied to slides for overnight at 4 degrees and they include anti-albumin (ICN 
Pharmaceuticals, Aurora, OH), Fluorescent detection was by Alexa Fluor® 488 
or Alexa Fluor® 594 conjugated secondary antibodies (Invitrogen, 
Carlsbad,CA). Nuclei were cross stained with 4',6-Diamidino-2-phenylindole 
(DAPI). Cell morphology was studied with Nikon Inverse phase contrast 
microscope and Immunofluorescence was captured by Olympus DP70 
immunofluorescent microscope and Confocal Olympus inverted microscope. 
Positive cells was determined by manual counting of positive immunofluorescent 
cells to DAPI positive nucleus in 3 separate random fields (at 40X magnification 
objective) on the Olympus microscope. 
5.2.3 Masson's trichrome staining. 
The sections were stained with Masson's trichrome method which was used to 
distinguish and analyze for cavernous smooth muscle (stained in red) and 
collagen (blue) and expressed as the ratio of cavernous smooth muscle/collagen. 
5.2.4Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA is the abbreviation of enzyme-linked immunosorbent assay. It is a useful 
and powerful method in estimating ng/ml to pg/ml ordered materials in the 
solution, such as serum, urine, sperm and culture supernatant. The basic principle 




of an ELISA is to use an enzyme to detect the binding of antigen (Ag) antibody 
(Ab). The enzyme converts a colorless substrate (chromogen) to a colored 
product, indicating the presence of Ag:Ab binding. An ELISA can be used to 
detect either the presence of Ags or Abs in a sample, depending on how the test 
is designed.   
Human albumin concentrations from culture media were measured by the 
sandwich enzyme-linked immuno-sorbent assay as previously described. The 
capture antibody (goat anti-human antibody; 4 mg/mL), the detection antibody 
(peroxidase-conjugated goat immunoglobulin G fraction to human albumin; 3 
mg/mL), and the purified human albumin standards were purchased from ICN 
Pharmaceuticals (Durham, NC).  
5.2.5 Cirrhotic liver injury model  
We have used the NSG mice for our cirrhotic live model for this study. N=3. 




/SzJ) with deleted B cells 
and T cells were obtained under MTA from the Jackson laboratory and bred in 
animal unit NUS that were used in transplantation experiment. Liver injury was 
induced by feeding the mice with Thioacetamide (TA) every day from 3 month 
to 10 months to induce liver cirrhosis.  
Mouse histology was examined at 3 month, 4 month, 6 month and at 10 month 
and then the mice were sacrificed thereafter. Sirius red, trichrome staining and 
H&E stains were performed to understand the cellular architecture of changes in 
liver.  H&E staining show a disorganized lobule formation. The changes in the 




bridging of portal were analyzed with trichrome staining (Figure 5.2, Figure 5.3 
and Figure 5.4).   
5.2.6 Site of delivery to target organ  
Fetal liver progenitor cells transplantation was performed via intrasplenic route. 
The intrasplenic route is technically easier and has been shown that almost all 
cells will migrate over to the liver by 24 hours.  It has been previously 
demonstrated that the portal vein network traverses through the liver cords via 
the portal tract. The transplanted cells enter the hepatic parenchyma through this 
Protal vein. 
5.2.7 Transplantation  
Nod-scid gamma mice at 3 months were treated with 200ug/L of thioacetamide 
in drinking water each day till the sacrifice of the mice. Transplanted mice were 
administered with 2 million human fetal liver progenitor cells enriched in 
primary fetal liver cultures via the intrasplenic route. Control animals were given 
sham surgery but infused with equivalent 0.2 ml phosphate buffered saline 
intrasplenically. Mice were then sacrificed at 4
th
 month in order to determine if 
human progenitor cells persisted and followed up at month 10 to track the 
repopulation levels.    
Results: 
To realize the translational relevance, it is key to understand, what signals would 
the transplanted human fetal liver progenitor cells produce to integrate, 
differentiate and function like normal differentiated cells. 




5.3 Localizing the engrafted human cells  
5.3.1Human specific albumin to identify human hepatocytes  
The transplanted cells were examined by immunofluorescence labeling with 
human albumin marker in mouse liver tissues. In mouse liver tissues, presence of 
human cell clusters was stained with albumin (Figure 5.5).  
5.3.2 Functions of in-vivo human cells  
Our aim is to demonstrate the ability of liver to restore its functions and identify 
the signals involved in the restoration of the liver cell populations.  
5.3.4 Production of albumin into serum  
Albumin production into the serum is a core function of hepatocytes and plays 
the role of carrier proteins for both nutrients and toxins as well as maintenance of 
oncotic pressure. The result from ELISA shows that the serum albumin levels 
were restored to normal levels in transplanted animals compared to control mice 
(Figure 5.6A).  
5.3.5 Liver Function Test 
Additionally we have shown that liver function on these rats improved. Blood 
was collected from the animals to study the liver functional test, namely periodic 
total bilirubin (TBIL) (Figure 5.6B).  
5.5 Interpretation  
SCID mice were used for these experiments as they were bred especially for 
human cell transplants. Human fetal liver cells are able to repopulate cirrhotic 
liver of mouse model of liver injury. They survive and differentiate into 




functional liver cells, integrating with mouse hepatocytes. They express albumin, 
total bilurubin. In the transplanted cirrhotic animal model, we observed the 
upregulation of the SHH gene. Hence, we conclude that the SHH gene may have 
a potential role in driving the transplanted hepatocytes to differentiate and 
recover liver function. 
 
 




Figure 5.1  mRNA-expression levels of in developmental stages and cirrhotic 
liver were measured by real-time-PCR experiment.  
 
cDNA was converted from first strand cDNA kit. The expression was normalized 
with the endogenous control of GAPDH. The comparison was made human 
normal adult liver control. The data shows the similarity of cirrhotic liver with 
week 22 of developmental stage. We notice the up regulation of stem cell 
transcriptional factors (OCT4, SOX2, NODAL and NANOG), IHH gene, FGF8, 
BMP3, T (brachury) and HNF1b. The interesting gene that we noticed was that 











































Figure 5.2  Liver cirrhosis model:  
Photomicrographs of a section of the liver of group II rats showing: a 




























Figure 5.3  Sirius red staining showing the irreversible cirrhosis in animals. 
 The formalin/paraffin sections of liver tissue free of tumor nodules were stained 
with Sirius red. Each figure is a representative picture of three animals in each 
group at each time point. The collagen deposition was stained in red. 
 
 




















Figure 5.4 Masson trichrome stain.  
 Fibrous connective tissue septa are noted bridging the portal areas and extending 










Figure 5.5 albumin in Immunofluorescence staining 
 Sections of transplanted mouse month 4 and month 6 post- transplant show 
























Figure 5.6 Liver function test 
 Liver function test shows the transplanted animals regain its functional 
properties. A. Albumin, B. Total Bilurubin. T -  Transplanted, C- Control, M- 

























In the past few decades, detailed analyses of liver development have been 
performed with various animal models tracing the formation of the liver from 
definitive endoderm to the mature liver. However, systematic analysis of the key 
genetic determinants that drive human fetal liver development has never been 
performed in such a systematic manner. Taking this into account, we demonstrate 
systematically, the molecular mechanism and its regulatory profile in developing 
human fetal liver. Insights into Human fetal liver development holds great 
promise in allowing us to apply the understanding of development of human 
hepatocytes to our efforts in expanding and growing hepatocytes ex vivo. This 
will enhance the culturing techniques by identifying the key signals such as 
signaling factors, growth factors and extracellular matrix niche. This is of critical 
importance as we embark on efforts to convert ES and IPS cells along their 
natural differentiation route and will hopefully allow us to break through the 
impasse to develop fully functional liver cells.  
In our research we had unique privileged access to collect human fetal liver with 
full consent from the KK Women and Children's Hospital. We have used mid 
gestational weeks from 10 week till 23 week in this study. We determined the 
global gene expression profiles for each stage of the developmental process and 
applied state of the art gene interrogation to understand the genetic determinants 
controlling the development of the fetal liver.  
 Based on these data, we defined a subset of mRNAs whose detection can be 





maturation of human fetal liver. In addition to being useful for phenotypic 
analyses, defining the gene expression profile for each stage will probably 
facilitate the identification of molecular pathways with undefined roles during 
human hepatocyte differentiation. 
6.1 what are the regulatory phases of human fetal liver development?  
We have observed that human fetal liver express five different phases in mid 
gestational period from week 10 till week 23. Comparison was made with 
embryonic Day 0 and contrasted with adult normal livers. Classical 
understanding of human fetal development has depended on 
immunohistochemistry and focus has been on the liver architecture. Similarly, we 
were able to observe what has been described of the ductal plate developing from 
a primitive structure at week 14 into a complete portal triad at week 22. Animal 
experiments have resulted in conventional concept of epithelial progenitor cells 
becoming hepatoblasts and progressively maturing into hepatocytes. Although a 
progenitor population has been described in fetal liver (Zhang et al), when and 
where this population arises from and the interactions with the hematopoietic 
phase is poorly understood.  
Using immunophenotyping and transcript signature, 5 phases were discernible in 
fetal liver development:  
(1) Stem cell specification phase till 10 weeks;  





(3) Hematopoiesis from 14 to 18 weeks 
(4) Second wave of progenitor proliferation from 18 to 22 weeks 
(5) Maturation from week 22 onwards to adult liver. 
6.1.1 stem cell and hepatoblast specification phase  
During 10 weeks we see the EpCAM cells appear surrounding the ductal plates 
which confirms the previous studies showing the ductal plates give rise to 
EpCAM+ stem cells. The EpCAM cells are believed to migrate outwards and 
differentiate into expanding hepatoblast that is seen around week 14.   The 
EpCAM expression reduces in week 18 during the hematopoiesis phase and 
resurges in progenitor cell proliferation phase during week 22. CD44+ and 
CD133+ stem cells strongly express during week 10 consistent with a generic 
stem cell genotype. These stem cells genes including OCT4, SOX2, NODAL 
continue to be strongly upregulated from week 10 to week 14 and the expression 
is consistent with continued proliferation of the stem cells. At this stage, we also 
see upregulation of HNF1A genes indicating specification into the liver lineage. 
The surge in AFP and albumin at week 10-14 is consistent with observation of 
clusters of AFP + cells emanating from the ductal plate.  
6.1.2 Hematopoietic phase  
Human fetal liver acts as a primary hematopoietic organ during organogenesis.  
Hematopoietic cells reside in liver during the prenatal stage and move to the bone 
marrow during postnatal stage. Fetal liver Immunofluorescence CD45 staining 





hematopoietic cells surge in numbers during the 18 weeks of fetal liver 
development around the ductal plates and portal tracts and these population of 
cells dwindle in expression from week 20 onwards. The microenvironment in the 
liver changes where OSM gene secreted from hematopoietic cells induce the 
hepatic transcriptional factors such as HNF and HGF growth factor for 
hepatocyte differentiation and proliferation.  We found that the hematopoietic 
stem cell activating factor XSIT up regulated during  week 18, however XSIT 
repressor gene TISX highly up regulate to suppress the transcriptional activity. 
This change in microenvironment is suitable for hepatic proliferation where the 
hematopoietic stem cells leave the liver and reside in bone marrow.  
6.1.3 Maturation and Expansion 
After the exodus of hematopoietic stem cells, hepatocytic maturation factors such 
as OSM, HGF and FGFR1 signaling is up regulated together with  JAK-STAT 
pathway in week 22. JAK-STAT pathway is important in maturation and 
differentiation during embryogenesis. During this phase we see the upregulation 
of epithelial growth factor EGF that is an important factor in epithelial cell 
maintenance.  
6.2 Transcriptional regulation of Human fetal liver development 
In addition to the genetic variation  that are regulated in different stages we have 
determined the key genes that are upregulated during different stages of 
development. The key transcription factors that showed greater than 2-fold up 





specification and these had a sudden up regulation from 22 weeks onwards with 
all the important genes like SHH, DLL, DLX, PATCH, NODAL involved in 
Hedge hog pathway were upregulated in week 22. At 18-21 weeks, EGF, FGF4, 
BMP3 and extracellular matrix genes like COL12A1, COL7A1, ITGA3, LAMA3 
were upregulated >2 fold compared to 14 and 22 weeks of fetal liver as well as 
normal liver. At 22 weeks the stem cell genes like POU5F1, SOX2, CD44, 
NANOG are significantly upregulated compared to 10 weeks in 22 samples.  
6.3. In vitro evidence of differentiation and maturation of fetal liver 
In addition to providing proof-of-concept we have demonstrated the in vitro 
application of growth factors (FGFr and CTGF) Extracellular matrix (collagen, 
lamanin and hyualuranic acid) that can be used as an efficient tool to probe 
human fetal cell fate. We exploited the use of growth factors CTGF and ECM 
proteins  in controlling the onset of human hepatocyte differentiation and 
expansion.                                                                                                                                                                          
6.3.1 Optimizing cultures to ECM and growth factors  
Recently the focus on controlling the microenvironment of the in vitro plating 
has provided remarkable progress in cell culture techniques to stimulate 
proliferation and maturation of cell functions. However, the drawbacks of using 
current techniques,  is difficult to maintain long-term expression of liver-specific 
functions.  Previous studies are shown to demonstrate the reconstruction of 
culture systems to more closely mimic the native in vivo microenvironment using 





specific functions of primary rat hepatocytes. It is therefore effective to mimic 
the in vivo microenvironment for ensuring expression of organ-specific functions 
and stem cell differentiation. 
We have used collagen, lamanin and Hyauronic acid as a basement support 
combination to promote human growth and differentiation. Human Fetal liver 
Cells were collected freshly and dissociated for culture. Our results have shown 
successful maintenance of human fetal liver cells using a combination of 
collagen and lamanin but lost its phenotypic characteristics when cultured in 
hyaluronic acid. Cell-cell contact appears to be critical for maintenance of these 
cells. The  limitation of using specific ECM isoforms like collagen and lamanin 
are the availability of these products in market.  The ability to create the exact 
isoform of the collagen molecules and lamanin will give better microenvironment 
required for the liver cell development.  
Modern molecular techniques have showed that members of the fibroblast 
growth factor family FGF1 and FGF2 in inducing the onset of albumin 
expression, a characteristic marker of hepatic cell fate in explants of mouse 
anterior endoderm. FGF growth factors have shown to mediate specification of 
hepatic cell fate in a concentration dependent manner in cell culture. FGF is also 
appearing to be controlled by endoderm relative to the heart, which is the major 
source of hepatogenesis FGF during liver development. Several FGFs including 
Fgf1, Fgf2, Fgf8, and Fgf10 are expressed in the mesoderm during 
hepatogenesis, and knockout studies in mice suggest that these factors play an 





signaling in controlling the onset of liver development is evolutionarily 
conserved, with FGFs displaying hepatogenic properties in Xenopus, chick, and 
Zebrafish embryos. We show in our study the importance of the FGF receptors 
FGFR1 and FGFR2. We showed that the blocking of these receptors with the 
specific antibodies has control in expansion and proliferation of the fetal liver 
cells. The FGFR blocking has increased the expansion of the liver cells in culture 
from more than a month without losing their phenotypic characteristics. 
6.4. Potential of therapeutic effect of cell transplantation 
To document principle of proof of fetal liver cells in being  to have a therapeutic 
effect, we created animal model using thioacetamide (TA) diet to create 
progressive liver injury. Fetal liver cells were transplanted and showed 
improvement in liver function and reversal of fibrosis. While this served as 
principle of proof that cell transplantation may benefit patients with liver 
cirrhosis. The current challenge is to find appropriate sources of cells and yet 
being able to differentiate them into functional hepatocytes. Using the somatic 
progenitor cell as an example, we were able to precisely profile the cells and map 
the cells in the progeny pathway of liver differentiation. This allows a systematic 
approach for specific manipulation to move these cells along the differentiation 
pathway.  
6.5 Limitations 
As we have discussed the important findings of our study, we have few points to 





1. Though we state an in depth analysis of the mid gestational period of liver 
development, we observed the maturation of the liver is not yet complete at week 
22. In real life, liver maturation continues in neonate up to 12 years old before 
the hepatocytes become fully mature. The clinical material from these time points 
are lacking due to ethical concerns and practical issues. This period of 
development would be very crucial in understanding the important maturational 
signal and extracellular niche that maintain the functional hepatocyte as well 
drive the maturation. 
2. Similarly human data from ES cells till week 10 are not easily studied in vivo 
and what is understood is extrapolated from animal models. 
3. Rather than a simple system of best or fixed combination of extracellular 
matrix to support ex-vivo culture, the in vivo micro environmental niche is likely 
complex where the extracellular matrix composition is dynamic and changes 
temporally as well as spatially in different parts of the fetal liver. Whole tissue 
RNA analysis does not allow that degree of resolution. Even the recapitulation of 
the dynamic ECM environmental niche will be difficult to replicate in ex-vivo 
culture.   
4. When we use whole fetal tissue samples as the source there are chances that 
we are focusing on the mixed cell population in the fetal liver development, 
where the gene expressional change in the cell (hepatocytes) that we are 






5. In our genetic array study we have used 2-fold change as the threshold for the 
upregulation of the genes. This is based on conventional and practical 
assumptions that some of the important master regulator transcriptional factors 
are highly expressed in fold change more than 2 fold. There is thus, a real chance 
of missing out the important factors that may be critically and finely regulated 
but below the 2-fold change threshold.   
6. Microarray analysis typically suffers from dangers of reductionist approach in 
inevitable complexities of biological systems..One example is the FGF signaling.  
We have shown that the FGF signaling is upregulated in the development but yet 
in vitro, the process is complex with growth factors, receptors upregulation, 
redundancy etc.  Such complex systems cannot be unraveled by genetic studies. 
Nevertheless, the hope is that there will be several key regulators that can be 





6.6 Future Directions  
1. We have noticed the sudden upregulation of EpCAM positive populations 
of cells in week 22. We have shown them to be the mesenchymal 
epithelial positive populations. The next questions we ask is that 1. What 
are these cells? And 2. What is the source of these cells? In order to 
identify the source of the cells we can use Cre-lox study for cell fate 
mapping in the animal model. Use 14 week, 18 week and 22 week non-
parenchyma cells to identify the nature and source of the cells that are 
undergoing mesenchymal epithelial transition. 
2. In our in vitro chapter we have described about the SHH gene is 
important in differentiation of the hepatocytes. This data is currently not 
congruent with current literature.  Further validation is needed to see   
whether the cells with and without SHH produce the hepatic cells. We 
need to fate map the cells with cre-lox SHH gene and transplant them in 
vitro to study the differentiation. 
3. The physiological roles of liver progenitor cells at 18-22 weeks continue 
to be an interesting question. Do they contribute much to the adult 
hepatocyte fraction? Do they play a pure reserve role in repair?. Cre-lox 
MET tracing of fetal liver progenitor cells in animal fetal models will be 
useful in defining this.  
4. From our microarray data we have noticed a broad spectrum of genes that 





it in liver. This widens the gap in knowledge about the new genes that can 
be studied in liver development. Similarly the new avenue of miRNA 
profiling in liver development is subject of open question. Here we 
propose to identify the miRNA profiling of the human fetal liver 






Human fetal liver from 11 weeks to 24 weeks gestation were obtained and 
analysed with IHC, microarray, next generation sequencing and qRT PCR for 
growth factor, extracellular matrix and liver specification transcriptional factors. 
Comparison was made with 10 week fetal liver and normal adult liver. Using 
immunophenotyping and transcript signature, 5 phases were distinguished and 
categorized in fetal liver development. Fetal liver progenitor cell undergoes 
proliferation at 10 to 14 week gestation, from 14 to 18 weeks differentiation of 
fetal hepatic lineage - the hepatoblast form, in week 18 there are signs of 
hematopoietic lineage expression from liver and from week 20 onwards there is a 
sudden proliferation of EpCAM and Vimentin positive cells, which is seems to 
be a mesenchymal lineage. 
EPCAM/CD44+ progenitor cells appear at 10 weeks and undergo surge in 
proliferation at 18-20 weeks of gestation before dwindling in frequency. The 
expression pattern of EPCAM corroborate that there are distinct phases such as 
progenitor cell population surge at 10 weeks, hepatoblast proliferation from 10 to 
14 weeks, hematopoietic phase at 15-18 weeks and reactivation to 22 weeks. This 
suggests that epithelial cell proliferation appears to take a backstage during the 
hematopoietic phase but undergo a second wave of progenitor cell proliferation 
with resurgence with termination of the hematopoietic phase. This was 
accompanied by increase in albumin and CYP450 gene expression compared to 





Week 10-11 Specification phase - genes at this stage were mostly embryonic 
stem cell factors and would be useful for in vitro IPSC manipulation. Week 14-
15: Expansion / differentiation phase - Genes at this stage were extracellular 
matrix proteins Collagen, Laminin and Hyaluronic acid. Week 17-19: 
Hematopoiesis and Proliferation Week 20-24: Maturation, EMT phase - genes 
that were upregulated at this stage were FGF, FGFR and CTGF. Adult Liver: 
functional. Specifically, week 11 to 14 would represent the phase of hepatoblast 
playing the role of a transit-amplifying cell in expansion and differentiation into 
hepatic lineage. Similarly, week 19 to 22 would represent the phase of progenitor 
cell proliferation by mesenchymal epithelial transition. Week 23 to adult would 
represent the phase of hepatocyte maturation.  
We have also identified key genes in each phase and are classified under 
transcriptional factors (GATA4, FOXA2 and CEBPa), growth factors (FGFR and 
CTGF) and extracellular matrix (COL12A1, LAMA3, Fibronectin and Hyurolic 
Acid). The transcriptional factors were identified as key signaling factors that are 
important in direct reprogramming of fibroblast to hepatocytes. To test if SHH 
was driving the differentiation, SHH supplementation in fetal liver cultures 
showed differentiation with maintenance of immunophenotyping. Inhibiting the 
SHH resulted in proliferation and expansion of liver cells.  These liver cells were 
transplanted into SCID mice treated with thioacetamide and the degree of 
repopulation was analyzed and correlated with growth factors and extracellular 
growth matrix. In vivo transplantation of these cells in mice livers showed 





in understanding their key regulation of liver development will help in expanding 
progenitor cells for regenerative purposes. With further validation these kind of 
systematic analysis will be a useful in identifying the key genes that would be 
essential in regenerative medicine.




Liver Specific Growth Factors Extra cellular Matrix 
ALB APOF ABCG2 KAT2A ADAMTS1 LAMB1 
CDH1 T ACTC1 GDF2 ADAMTS13 LAMB3 
CYP2C9 CEBPA ADAR GDF3 ADAMTS8 LAMC1 
GSK3A CEBPB ACAN GJA1 CD44 MMP1 
LTA CYP2B6 ALDH1A1 GJB1 CDH1 MMP10 
SERPINA1 CYP3A4 ALDH2 GJB2 CNTN1 MMP11 
ABCB11 CYP7A1 ALPI HDAC2 COL11A1 MMP12 
CEBPA EGF APC HSPA9 COL12A1 MMP13 
CYP2D6 EOMES ASCL2 IGF1 COL14A1 MMP14 
MMEX FGFR2 AXIN1 PDX1 COL15A1 MMP15 
MIXL1 FOXA1 BGLAP ISL1 COL16A1 MMP16 
SOX2 G6PC BMP1 JAG1 COL1A1 MMP2 
ADH1C GATA4 BMP2 KRT15 COL4A2 MMP3 
CPS1 GATA6 BMP3 MME COL5A1 MMP7 
CYP2E1 GLI1 BTRC MSX1 COL6A1 MMP8 
KLF4 GLI2 CCNA2 MYC COL6A2 MMP9 
NANOG GLI3 CCND1 MYOD1 COL7A1 NCAM1 
SOX7 HGF CCND2 KAT8 COL8A1 PECAM1 
AFP HNF1A CCNE1 KAT7 VCAN SELE 
RY2 HNF1B CD3D NCAM1 CTGF SELL 
DLK1 HNF4A CD4 NEUROG2 CTNNA1 SELP 
KLHL1 IHH CD44 NOTCH1 CTNNB1 SGCE 
NCAM1 KRT7 CD8A NOTCH2 CTNND1 SPARC 
TSPAN7 KRT18 CD8B NUMB CTNND2 SPG7 
ANXA10 ONECUT2 CDK1 SIGMAR1 ECM1 SPP1 
CTNNB1 OSM CDC42 PARD6A FN1 TGFBI 
EPCAM PCK2 CDH1 PPARD HAS1 THBS1 
KRT19 PDGFRB CDH2 PPARG ICAM1 THBS2 




NODAL PROM1 COL1A1 RB1 ITGA1 THBS3 
GADPH PROX1 COL2A1 S100B ITGA2 TIMP1 
BMP4 PTCH1 COL9A1 SOX1 ITGA3 TIMP2 
CXCR4 PTCH2 CTNNA1 SOX2 ITGA4 TIMP3 
FGF8 SHH CXCL12 T ITGA5 CLEC3B 
KRT7 SMAD2 DHH TERT ITGA6 TNC 
OTC SMAD3 DLL1 TUBB3 ITGA7 VCAM1 
GDC SMAD4 DLL3 WNT1 ITGA8 VTN 
CD24 SMAD5 DTX1 B2M ITGAL B2M 
CYP1A2 SMO DTX2 HPRT1 ITGAM HPRT1 
GJB1 SOX17 DVL1 RPL13A ITGAV RPL13A 
LGR5 TAT EP300 GAPDH ITGB1 GAPDH 
PCK1 TGFB2 FGF1 ACTB ITGB2 ACTB 
RTC TGFB3 FGF2 HGDC ITGB3 HGDC 
CD44 THY1 FGF3 RTC ITGB4 RTC 
CYP2C19 TTR FGF4 RTC ITGB5 RTC 
GSC GAPDH FGFR1 RTC KAL1 RTC 
LGR6 HGDC FOXA2 PPC LAMA1 PPC 
POU5F1 RTC FRAT1 PPC LAMA2 PPC 
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